[
  {
    "objectID": "eda2.html#idf-metabolic-syndrome-definition",
    "href": "eda2.html#idf-metabolic-syndrome-definition",
    "title": "Data Processing & EDA",
    "section": "IDF Metabolic Syndrome Definition",
    "text": "IDF Metabolic Syndrome Definition\nNote: Below, the MetS IDF definition is not fully using the imputed biochemical information to decide on whether an individual belongs to the NO or YES groups for having metabolic syndrome.\n\n\n\n\n\n\nMetabolic Syndrome Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nClinical Variable\nN\nOverall\nN = 1531\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nGender\n153\n\n\n\n\n\n\n0.009**\n\n\n    Female\n\n\n99 (65%)\n84 (70%)\n15 (45%)\n\n\n\n\n    Male\n\n\n54 (35%)\n36 (30%)\n18 (55%)\n\n\n\n\nSite Collection\n153\n\n\n\n\n\n\n0.881\n\n\n    AUTH\n\n\n32 (21%)\n25 (21%)\n7 (21%)\n\n\n\n\n    BILBAO\n\n\n19 (12%)\n16 (13%)\n3 (9.1%)\n\n\n\n\n    CORK\n\n\n50 (33%)\n40 (33%)\n10 (30%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n19 (16%)\n5 (15%)\n\n\n\n\n    UVEG\n\n\n28 (18%)\n20 (17%)\n8 (24%)\n\n\n\n\nBMI\n153\n30.6 (28.5, 34.9)\n29.6 (27.8, 33.2)\n34.9 (32.4, 38.8)\n&lt;0.001***\n\n\nTRIG\n153\n69 (48, 116)\n61 (45, 102)\n93 (66, 136)\n0.007**\n\n\nHDL\n149\n53 (44, 62)\n54 (47, 63)\n43 (38, 51)\n&lt;0.001***\n\n\n    Missing\n\n\n4\n4\n0\n\n\n\n\nGLU\n149\n91 (84, 97)\n90 (83, 95)\n101 (90, 106)\n&lt;0.001***\n\n\n    Missing\n\n\n4\n3\n1\n\n\n\n\nHighBP\n150\n105 (70%)\n75 (64%)\n30 (91%)\n0.003**\n\n\n    Missing\n\n\n3\n3\n0\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s Chi-squared test; Fisher’s exact test; Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#biochemical-measurements",
    "href": "eda2.html#biochemical-measurements",
    "title": "Data Processing & EDA",
    "section": "Biochemical Measurements",
    "text": "Biochemical Measurements\nNote: Below, the MetS IDF definition is not fully using the imputed biochemical information to decide on whether an individual belongs to the NO or YES groups for having metabolic syndrome.\n\n\n\n\n\n\nBiochemical Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nBiochemical Variable\nN\nOverall\nN = 1531\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nSite_Collection\n153\n\n\n\n\n\n\n0.881\n\n\n    AUTH\n\n\n32 (21%)\n25 (21%)\n7 (21%)\n\n\n\n\n    BILBAO\n\n\n19 (12%)\n16 (13%)\n3 (9.1%)\n\n\n\n\n    CORK\n\n\n50 (33%)\n40 (33%)\n10 (30%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n19 (16%)\n5 (15%)\n\n\n\n\n    UVEG\n\n\n28 (18%)\n20 (17%)\n8 (24%)\n\n\n\n\nCHOL\n153\n203 (184, 233)\n209 (189, 236)\n193 (173, 217)\n0.018*\n\n\nTRIG\n153\n69 (48, 116)\n61 (45, 102)\n93 (66, 136)\n0.007**\n\n\nHDL\n153\n53 (44, 61)\n54 (48, 63)\n43 (38, 51)\n&lt;0.001***\n\n\nHDL_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nLDL\n153\n139 (113, 158)\n140 (116, 161)\n126 (102, 151)\n0.097\n\n\nLDL_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nHbA1c_Perc\n153\n5.60 (5.35, 5.90)\n5.50 (5.31, 5.75)\n5.85 (5.60, 6.20)\n&lt;0.001***\n\n\nHbA1c_Perc_Detected\n153\n151 (99%)\n118 (98%)\n33 (100%)\n&gt;0.999\n\n\nGLU\n153\n91 (84, 97)\n90 (83, 95)\n101 (91, 105)\n&lt;0.001***\n\n\nGLU_Detected\n153\n149 (97%)\n117 (98%)\n32 (97%)\n&gt;0.999\n\n\nUREA\n153\n29 (24, 34)\n29 (24, 34)\n29 (24, 33)\n0.812\n\n\nUREA_Detected\n153\n\n\n\n\n\n\n\n\n\n\n    Yes\n\n\n153 (100%)\n120 (100%)\n33 (100%)\n\n\n\n\nCREA\n153\n0.79 (0.70, 0.90)\n0.78 (0.70, 0.90)\n0.81 (0.70, 1.00)\n0.189\n\n\n25_OH_Vit_D3\n153\n23 (19, 27)\n23 (20, 27)\n23 (19, 27)\n0.413\n\n\n25_OH_Vit_D3_Detected\n153\n104 (68%)\n82 (68%)\n22 (67%)\n0.856\n\n\nALB\n153\n4.40 (4.10, 4.69)\n4.40 (4.12, 4.70)\n4.37 (4.00, 4.59)\n0.230\n\n\nALB_Detected\n153\n152 (99%)\n119 (99%)\n33 (100%)\n&gt;0.999\n\n\nTBIL\n153\n0.54 (0.41, 0.75)\n0.55 (0.40, 0.76)\n0.53 (0.43, 0.70)\n0.868\n\n\nTBIL_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nNa\n153\n140.00 (139.00, 142.00)\n140.00 (138.40, 141.60)\n141.00 (139.00, 142.00)\n0.079\n\n\nK\n153\n4.47 (4.20, 4.70)\n4.50 (4.20, 4.70)\n4.40 (4.20, 4.66)\n0.582\n\n\nK_Detected\n153\n151 (99%)\n118 (98%)\n33 (100%)\n&gt;0.999\n\n\nCRP\n153\n0.28 (0.12, 0.91)\n0.27 (0.12, 0.79)\n0.58 (0.22, 1.00)\n0.107\n\n\nCRP_Detected\n153\n\n\n\n\n\n\n\n\n\n\n    Yes\n\n\n153 (100%)\n120 (100%)\n33 (100%)\n\n\n\n\nWBC\n153\n6.20 (5.17, 7.66)\n6.04 (5.14, 7.82)\n6.56 (5.31, 7.48)\n0.719\n\n\nRBC\n153\n4.74 (4.48, 5.02)\n4.65 (4.37, 4.93)\n4.92 (4.77, 5.27)\n&lt;0.001***\n\n\nHCT_Perc\n153\n42.7 (40.0, 44.8)\n41.6 (39.7, 44.1)\n44.0 (43.0, 46.0)\n0.005**\n\n\nHGB\n153\n14.10 (13.10, 15.10)\n14.00 (13.00, 15.00)\n14.90 (13.70, 15.50)\n0.020*\n\n\nNEU_Perc\n153\n57 (51, 62)\n57 (50, 62)\n58 (51, 62)\n0.506\n\n\nLYM_Perc\n153\n32 (28, 37)\n32 (28, 37)\n32 (26, 37)\n0.613\n\n\nMONO_Perc\n153\n7.30 (5.90, 9.10)\n7.40 (5.90, 9.12)\n7.20 (5.90, 8.90)\n0.638\n\n\nBASO_Perc\n153\n0.80 (0.60, 1.27)\n0.85 (0.60, 1.31)\n0.80 (0.52, 1.00)\n0.419\n\n\nBASO_Perc_Detected\n153\n142 (93%)\n111 (93%)\n31 (94%)\n&gt;0.999\n\n\nEOS_Perc\n153\n2.80 (1.64, 3.92)\n2.66 (1.63, 3.94)\n3.10 (1.70, 3.85)\n0.837\n\n\nEOS_Perc_Detected\n153\n151 (99%)\n118 (98%)\n33 (100%)\n&gt;0.999\n\n\nMVC\n153\n90.1 (86.5, 93.0)\n90.4 (86.9, 93.2)\n87.5 (85.3, 92.3)\n0.102\n\n\nMCH\n153\n30.00 (29.00, 31.00)\n30.20 (29.00, 31.00)\n29.50 (28.00, 30.40)\n0.028*\n\n\nMCHC\n153\n33.30 (32.50, 34.10)\n33.20 (32.55, 34.20)\n33.60 (32.50, 34.00)\n0.829\n\n\nRDW_CV_Perc\n153\n13.00 (12.30, 13.70)\n12.90 (12.25, 13.70)\n13.20 (12.70, 13.70)\n0.172\n\n\nNEU\n153\n3.41 (2.74, 4.46)\n3.40 (2.74, 4.38)\n3.62 (2.90, 4.55)\n0.536\n\n\nLYM\n153\n1.91 (1.55, 2.38)\n1.91 (1.60, 2.42)\n1.97 (1.52, 2.31)\n0.564\n\n\nMONO\n153\n0.45 (0.39, 0.56)\n0.47 (0.39, 0.56)\n0.43 (0.39, 0.56)\n0.942\n\n\nBASO\n153\n0.050 (0.040, 0.080)\n0.050 (0.040, 0.080)\n0.050 (0.040, 0.060)\n0.571\n\n\nBASO_Detected\n153\n142 (93%)\n111 (93%)\n31 (94%)\n&gt;0.999\n\n\nEOS\n153\n0.17 (0.10, 0.25)\n0.17 (0.10, 0.25)\n0.18 (0.10, 0.25)\n0.986\n\n\nEOS_Detected\n153\n151 (99%)\n118 (98%)\n33 (100%)\n&gt;0.999\n\n\nPLT\n153\n265 (230, 301)\n269 (233, 308)\n252 (193, 292)\n0.062\n\n\nSGOT\n153\n23 (19, 27)\n23 (19, 26)\n25 (20, 29)\n0.076\n\n\nSGOT_Detected\n153\n129 (84%)\n101 (84%)\n28 (85%)\n0.924\n\n\nSGPT\n153\n28 (21, 34)\n28 (19, 34)\n30 (26, 54)\n0.019*\n\n\nALP\n153\n70 (56, 84)\n69 (54, 84)\n72 (58, 86)\n0.316\n\n\nALP_Detected\n153\n152 (99%)\n119 (99%)\n33 (100%)\n&gt;0.999\n\n\nTG_HDL_C_Index\n153\n1.34 (0.86, 2.24)\n1.16 (0.77, 1.90)\n2.16 (1.59, 3.09)\n&lt;0.001***\n\n\nTG_HDL_C_Index_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nTyG_Index\n153\n4.37 (4.16, 4.62)\n4.33 (4.12, 4.58)\n4.58 (4.37, 4.74)\n&lt;0.001***\n\n\nTyG_Index_Detected\n153\n149 (97%)\n117 (98%)\n32 (97%)\n&gt;0.999\n\n\nALT_AST_Ratio\n153\n1.18 (0.93, 1.53)\n1.12 (0.93, 1.48)\n1.33 (1.00, 1.78)\n0.046*\n\n\nALT_AST_Ratio_Detected\n153\n129 (84%)\n101 (84%)\n28 (85%)\n0.924\n\n\nCHOL_HDL_Ratio\n153\n3.89 (3.38, 4.59)\n3.76 (3.26, 4.54)\n4.12 (3.68, 4.98)\n0.016*\n\n\nCHOL_HDL_Ratio_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nAtherogenic_Index\n153\n0.13 (-0.06, 0.35)\n0.06 (-0.11, 0.28)\n0.33 (0.20, 0.49)\n&lt;0.001***\n\n\nAtherogenic_Index_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nAISI\n153\n225 (141, 308)\n223 (146, 298)\n236 (123, 327)\n0.884\n\n\ndNLR\n153\n1.31 (1.02, 1.64)\n1.30 (1.01, 1.66)\n1.37 (1.03, 1.61)\n0.507\n\n\nEBR\n153\n3.00 (2.00, 4.75)\n2.90 (2.00, 4.56)\n3.00 (2.00, 5.25)\n0.643\n\n\nEBR_Detected\n153\n141 (92%)\n110 (92%)\n31 (94%)\n&gt;0.999\n\n\nLMR\n153\n4.27 (3.41, 5.44)\n4.28 (3.45, 5.45)\n4.22 (2.93, 5.36)\n0.564\n\n\nMLR\n153\n0.23 (0.18, 0.29)\n0.23 (0.18, 0.29)\n0.24 (0.19, 0.34)\n0.564\n\n\nNLR\n153\n1.81 (1.36, 2.25)\n1.80 (1.35, 2.24)\n1.88 (1.42, 2.47)\n0.509\n\n\nPLR\n153\n134 (110, 166)\n138 (115, 167)\n127 (100, 165)\n0.228\n\n\nSII\n153\n462 (343, 617)\n464 (347, 619)\n453 (288, 563)\n0.560\n\n\n\nUnits are various: mg/dL, ng/mL, g/dL, mmol/L, 10^3/μL, 10^6/μL, %, 10^9/L and U/L. P-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Fisher’s exact test; Wilcoxon rank sum test; NA; Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#metabolic-syndrome-index",
    "href": "eda2.html#metabolic-syndrome-index",
    "title": "Data Processing & EDA",
    "section": "Metabolic Syndrome Index",
    "text": "Metabolic Syndrome Index\nBlood pressure data are imported as seen below:\n\n\n\n  \n\n\n\n\n\n\n\n\n\n\n\nFigure 1: Systolic Vs Diastolic Blood Pressure. The dashed pink lines denote the values above which a case is typically characterized as having metabolic syndrome. The purple line indicates the correlation between the two measurements, which is 55%.\n\n\n\n\n\nUsing the blood pressure data together with other measurements used for defining the metabolic syndrome, a score index can be derived as follows. For each input, a translation function is created to map each biomarker’s values between zero and one where zero is unacceptable and one is most desirable i.e. exceeding a given threshold. The mapping depends on whether high or low values are desirable. Each translation function has a parameter which is carefully selected so that each input threshold corresponds to either the 60% value or the 50% value (risk probability) of the translation function (see plots below for more clarity). The 60% threshold value is applied only to \\(\\geqslant\\) cases. The input thresholds as well as the desirability directions (\\(\\geqslant\\) or &gt; or &lt;) for defining the metabolic syndrome index are:\n\nBody Mass Index (BMI) : \\(\\text{ &gt; 30 }kg/m^2\\)\nTriglycerides (TRIG) : \\(\\text{ $\\geqslant$ 150 mg/dL}\\)\nHigh Density Lipoprotein (HDL) : \\(\\text{ &lt; 45 mg/dL}\\)\nGlucose (GLU) : \\(\\text{ $\\geqslant$ 100 mg/dL}\\)\nSystolic Blood Pressure (SBP) : \\(\\text{  $\\geqslant$ 130 mm Hg}\\)\nDiastolic Blood Pressure (DBP) : \\(\\text{  $\\geqslant$ 85 mm Hg}\\)\n\nThen all the translation function results are combined to form a final score for the metabolic syndrome. The combination is done in a manner that takes into account the varying degrees of each biomarker’s translation function.\nIn the below multi-plot panel the relation of the metabolic syndrome score and of the translation functions are shown for each biomarker.\n\n\n\n\n\n\n\n\n\n\n\n(a) Metabolic syndrome index score Vs Body Mass Index\n\n\n\n\n\n\n\n\n\n\n\n(b) Translation Function Vs Body Mass Index\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Metabolic syndrome index score Vs Triglycerides\n\n\n\n\n\n\n\n\n\n\n\n(d) Translation Function Vs Triglycerides\n\n\n\n\n\n\n\n\n\n\n\n\n\n(e) Metabolic syndrome index score Vs High Density Lipoprotein\n\n\n\n\n\n\n\n\n\n\n\n(f) Translation Function Vs High Density Lipoprotein\n\n\n\n\n\n\n\n\n\n\n\n\n\n(g) Metabolic syndrome index score Vs Glucose\n\n\n\n\n\n\n\n\n\n\n\n(h) Translation Function Vs Glucose\n\n\n\n\n\n\n\n\n\n\n\n\n\n(i) Metabolic syndrome index score Vs Systolic Blood Pressure\n\n\n\n\n\n\n\n\n\n\n\n(j) Translation Function Vs Systolic Blood Pressure\n\n\n\n\n\n\n\n\n\n\n\n\n\n(k) Metabolic syndrome index score Vs Diastolic Blood Pressure\n\n\n\n\n\n\n\n\n\n\n\n(l) Translation Function Vs Diastolic Blood Pressure\n\n\n\n\n\n\n\nFigure 2: Metabolic syndrome index score and translation functions for each biomarker.\n\n\n\n\n\n\n\n\n\n\n\nFigure 3: Histogram and density curve of the Metabolic Syndrome Score. The vertical dashed line denotes the median value which separates the higher from lower risk cases.\n\n\n\n\n\nNote: Below, the imputed biochemical information is used for deriving the metabolic syndrome MetS index.\n\n\n\n\n\n\nBiochemical Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nBiochemical Variable\nN\nOverall\nN = 1531\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nSite_Collection\n153\n\n\n\n\n\n\n0.124\n\n\n    AUTH\n\n\n32 (21%)\n17 (22%)\n15 (19%)\n\n\n\n\n    BILBAO\n\n\n19 (12%)\n7 (9.2%)\n12 (16%)\n\n\n\n\n    CORK\n\n\n50 (33%)\n28 (37%)\n22 (29%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n15 (20%)\n9 (12%)\n\n\n\n\n    UVEG\n\n\n28 (18%)\n9 (12%)\n19 (25%)\n\n\n\n\nCHOL\n153\n203 (184, 233)\n214 (189, 238)\n199 (175, 232)\n0.046*\n\n\nTRIG\n153\n69 (48, 116)\n56 (39, 80)\n93 (56, 130)\n&lt;0.001***\n\n\nHDL\n153\n53 (44, 61)\n60 (52, 73)\n46 (41, 53)\n&lt;0.001***\n\n\nLDL\n153\n139 (113, 158)\n140 (113, 160)\n139 (114, 158)\n0.688\n\n\nHbA1c_Perc\n153\n5.60 (5.35, 5.90)\n5.50 (5.30, 5.70)\n5.72 (5.44, 6.00)\n0.001**\n\n\nGLU\n153\n91 (84, 97)\n90 (81, 95)\n93 (86, 102)\n&lt;0.001***\n\n\nUREA\n153\n29 (24, 34)\n28 (22, 33)\n30 (25, 34)\n0.096\n\n\nCREA\n153\n0.79 (0.70, 0.90)\n0.78 (0.69, 0.86)\n0.80 (0.70, 1.00)\n0.014*\n\n\n25_OH_Vit_D3\n153\n23 (19, 27)\n23 (19, 28)\n23 (19, 26)\n0.357\n\n\nALB\n153\n4.40 (4.10, 4.69)\n4.34 (4.10, 4.70)\n4.40 (4.10, 4.60)\n0.682\n\n\nTBIL\n153\n0.56 (0.41, 0.75)\n0.59 (0.40, 0.73)\n0.53 (0.41, 0.76)\n0.749\n\n\nNa\n153\n140.00 (139.00, 142.00)\n140.00 (139.00, 142.00)\n140.00 (138.90, 141.10)\n0.722\n\n\nK\n153\n4.47 (4.20, 4.70)\n4.50 (4.25, 4.70)\n4.40 (4.20, 4.70)\n0.549\n\n\nCRP\n153\n0.28 (0.12, 0.91)\n0.22 (0.10, 0.55)\n0.39 (0.18, 1.30)\n0.008**\n\n\nWBC\n153\n6.20 (5.17, 7.66)\n5.73 (4.92, 7.45)\n6.56 (5.51, 7.82)\n0.074\n\n\nRBC\n153\n4.74 (4.48, 5.02)\n4.61 (4.30, 4.87)\n4.86 (4.60, 5.09)\n&lt;0.001***\n\n\nHCT_Perc\n153\n42.7 (40.0, 44.8)\n41.1 (38.9, 44.0)\n43.8 (40.5, 45.3)\n0.004**\n\n\nHGB\n153\n14.10 (13.10, 15.10)\n13.70 (12.90, 14.55)\n14.60 (13.70, 15.40)\n&lt;0.001***\n\n\nNEU_Perc\n153\n57 (51, 62)\n56 (49, 61)\n57 (52, 63)\n0.117\n\n\nLYM_Perc\n153\n32 (28, 37)\n32 (28, 37)\n31 (27, 36)\n0.332\n\n\nMONO_Perc\n153\n7.30 (5.90, 9.10)\n7.26 (5.84, 9.29)\n7.40 (6.10, 8.90)\n0.983\n\n\nBASO_Perc\n153\n0.70 (0.50, 1.00)\n0.71 (0.50, 1.30)\n0.70 (0.52, 0.96)\n0.686\n\n\nEOS_Perc\n153\n2.74 (1.61, 3.91)\n2.85 (1.63, 4.40)\n2.72 (1.60, 3.60)\n0.406\n\n\nMVC\n153\n90.1 (86.5, 93.0)\n91.0 (87.1, 94.0)\n89.7 (86.1, 92.5)\n0.063\n\n\nMCH\n153\n30.00 (29.00, 31.00)\n30.05 (29.00, 31.00)\n30.00 (28.70, 31.00)\n0.570\n\n\nMCHC\n153\n33.30 (32.50, 34.10)\n33.10 (32.50, 34.10)\n33.60 (32.60, 34.10)\n0.192\n\n\nRDW_CV_Perc\n153\n13.00 (12.30, 13.70)\n13.00 (12.25, 13.60)\n13.00 (12.40, 13.70)\n0.440\n\n\nNEU\n153\n3.41 (2.74, 4.46)\n3.25 (2.55, 4.06)\n3.69 (2.95, 4.60)\n0.035*\n\n\nLYM\n153\n1.91 (1.55, 2.38)\n1.90 (1.52, 2.36)\n1.96 (1.60, 2.47)\n0.590\n\n\nMONO\n153\n0.45 (0.39, 0.56)\n0.45 (0.39, 0.52)\n0.47 (0.39, 0.59)\n0.185\n\n\nBASO\n153\n0.05 (0.03, 0.07)\n0.05 (0.03, 0.07)\n0.05 (0.04, 0.06)\n0.993\n\n\nEOS\n153\n0.17 (0.10, 0.25)\n0.15 (0.10, 0.26)\n0.18 (0.10, 0.24)\n0.950\n\n\nPLT\n153\n265 (230, 301)\n267 (227, 303)\n263 (234, 301)\n0.997\n\n\nSGOT\n153\n23 (19, 27)\n23 (19, 27)\n23 (19, 27)\n0.891\n\n\nSGPT\n153\n28 (21, 34)\n28 (20, 34)\n29 (21, 42)\n0.201\n\n\nALP\n153\n70 (56, 84)\n69 (54, 86)\n71 (56, 83)\n0.783\n\n\nTG_HDL_C_Index\n153\n1.34 (0.86, 2.24)\n0.91 (0.59, 1.35)\n1.91 (1.34, 2.67)\n&lt;0.001***\n\n\nTyG_Index\n153\n4.37 (4.16, 4.62)\n4.25 (4.05, 4.40)\n4.58 (4.28, 4.70)\n&lt;0.001***\n\n\nALT_AST_Ratio\n153\n1.18 (0.93, 1.53)\n1.09 (0.87, 1.41)\n1.25 (0.95, 1.65)\n0.051\n\n\nCHOL_HDL_Ratio\n153\n3.89 (3.38, 4.59)\n3.58 (2.99, 4.15)\n4.45 (3.68, 4.90)\n&lt;0.001***\n\n\nAtherogenic_Index\n153\n0.13 (-0.06, 0.35)\n-0.04 (-0.23, 0.13)\n0.28 (0.13, 0.43)\n&lt;0.001***\n\n\nAISI\n153\n225 (141, 308)\n214 (127, 280)\n236 (157, 338)\n0.088\n\n\ndNLR\n153\n1.31 (1.02, 1.64)\n1.28 (0.97, 1.55)\n1.32 (1.08, 1.68)\n0.118\n\n\nEBR\n152\n3 (2, 6)\n3 (2, 6)\n4 (2, 5)\n\n\n\n\n    Missing\n\n\n1\n1\n0\n\n\n\n\nLMR\n153\n4.27 (3.41, 5.44)\n4.41 (3.48, 5.61)\n4.22 (3.21, 5.30)\n0.346\n\n\nMLR\n153\n0.23 (0.18, 0.29)\n0.23 (0.18, 0.29)\n0.24 (0.19, 0.31)\n0.346\n\n\nNLR\n153\n1.81 (1.36, 2.25)\n1.72 (1.33, 2.26)\n1.86 (1.46, 2.25)\n0.183\n\n\nPLR\n153\n134 (110, 166)\n138 (117, 162)\n132 (101, 172)\n0.611\n\n\nSII\n153\n462 (343, 617)\n462 (337, 566)\n470 (352, 653)\n0.340\n\n\n\nUnits are various: mg/dL, ng/mL, g/dL, mmol/L, 10^3/μL, 10^6/μL, %, 10^9/L and U/L. P-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s Chi-squared test; Wilcoxon rank sum test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nWhen comparing the metabolic syndrome IDF with the Score Index univariate statistics tables for the biochemical data, we see that the Score Index seems to produce results of stronger significance, and with a few notable differences such as the case of CRP.",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#human-body-measurements---devices",
    "href": "eda2.html#human-body-measurements---devices",
    "title": "Data Processing & EDA",
    "section": "Human Body Measurements - Devices",
    "text": "Human Body Measurements - Devices\nNote: Below, the imputed human body device information is used for comparing to the metabolic syndrome index.\n\n\n\n\n\n\nHuman Body Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nHuman Body Data Variable\nN\nOverall\nN = 1531\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nSite_Collection\n153\n\n\n\n\n\n\n0.124\n\n\n    AUTH\n\n\n32 (21%)\n17 (22%)\n15 (19%)\n\n\n\n\n    CBG\n\n\n19 (12%)\n7 (9.2%)\n12 (16%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n15 (20%)\n9 (12%)\n\n\n\n\n    TEAGASC\n\n\n50 (33%)\n28 (37%)\n22 (29%)\n\n\n\n\n    UVEG\n\n\n28 (18%)\n9 (12%)\n19 (25%)\n\n\n\n\ngender\n153\n\n\n\n\n\n\n0.003**\n\n\n    Female\n\n\n99 (65%)\n58 (76%)\n41 (53%)\n\n\n\n\n    Male\n\n\n54 (35%)\n18 (24%)\n36 (47%)\n\n\n\n\nage_value\n153\n1.94 (1.70, 2.30)\n1.92 (1.70, 2.25)\n2.00 (1.70, 2.30)\n0.839\n\n\nrisk_group_cardiovascular\n153\n\n\n\n\n\n\n0.025*\n\n\n    I\n\n\n57 (37%)\n21 (28%)\n36 (47%)\n\n\n\n\n    II\n\n\n15 (9.8%)\n10 (13%)\n5 (6.5%)\n\n\n\n\n    III\n\n\n3 (2.0%)\n3 (3.9%)\n0 (0%)\n\n\n\n\n    Normal\n\n\n78 (51%)\n42 (55%)\n36 (47%)\n\n\n\n\nai\n153\n-59 (-84, -31)\n-61 (-85, -25)\n-58 (-83, -32)\n0.780\n\n\nae\n153\n-77 (-85, -64)\n-78 (-86, -62)\n-77 (-84, -64)\n0.926\n\n\npe\n153\n-30 (-37, -19)\n-30 (-37, -18)\n-29 (-38, -20)\n0.798\n\n\nans_activity\n153\n107 (93, 126)\n112 (97, 133)\n101 (84, 119)\n0.010*\n\n\nans_balance\n153\n66 (34, 101)\n65 (38, 98)\n69 (34, 103)\n0.691\n\n\nstress_resilience\n153\n107 (90, 131)\n113 (95, 137)\n102 (84, 124)\n0.012*\n\n\nstress_index\n153\n92 (75, 108)\n88 (67, 100)\n96 (83, 114)\n0.003**\n\n\nfatigue_index\n153\n87 (68, 103)\n82 (66, 100)\n91 (74, 107)\n0.040*\n\n\nmean_hrt\n153\n71 (64, 79)\n67 (62, 76)\n74 (67, 83)\n0.002**\n\n\nelectro_cardiac_stability\n153\n108 (97, 128)\n115 (101, 130)\n105 (94, 118)\n0.014*\n\n\nectopic_beat\n153\n0.0 (0.0, 1.0)\n0.0 (0.0, 1.0)\n0.0 (0.0, 0.0)\n0.616\n\n\nsdnn\n153\n35 (25, 47)\n37 (29, 55)\n32 (23, 45)\n0.014*\n\n\npsi\n153\n44 (23, 75)\n35 (19, 62)\n51 (29, 98)\n0.004**\n\n\ntp\n153\n900 (463, 1,765)\n1,022 (658, 2,024)\n669 (330, 1,356)\n0.016*\n\n\nvlf\n153\n286 (165, 661)\n318 (183, 745)\n241 (129, 583)\n0.096\n\n\nlf\n153\n274 (138, 542)\n309 (152, 595)\n230 (105, 438)\n0.061\n\n\nhf\n153\n177 (96, 388)\n263 (110, 490)\n134 (69, 256)\n0.005**\n\n\nlfnorm\n153\n56 (42, 75)\n54 (40, 72)\n61 (46, 76)\n0.258\n\n\nhfnorm\n153\n44 (25, 58)\n46 (28, 60)\n39 (24, 54)\n0.260\n\n\nlf_hf_ratio\n153\n1.28 (0.73, 2.94)\n1.16 (0.68, 2.62)\n1.55 (0.86, 3.14)\n0.260\n\n\nrmssd\n153\n26 (18, 38)\n32 (22, 41)\n21 (14, 30)\n&lt;0.001***\n\n\napen\n153\n0.98 (0.82, 1.08)\n0.93 (0.79, 1.06)\n1.01 (0.86, 1.12)\n0.012*\n\n\nsrd\n153\n0.98 (0.90, 1.07)\n0.99 (0.89, 1.08)\n0.98 (0.91, 1.07)\n0.748\n\n\ntsrd\n153\n119 (88, 152)\n131 (111, 155)\n102 (78, 127)\n&lt;0.001***\n\n\ntp_ln\n153\n6.80 (6.14, 7.48)\n6.93 (6.49, 7.61)\n6.51 (5.80, 7.21)\n0.016*\n\n\nvlf_ln\n153\n5.66 (5.10, 6.49)\n5.76 (5.21, 6.61)\n5.49 (4.86, 6.37)\n0.095\n\n\nlf_ln\n153\n5.60 (4.93, 6.30)\n5.73 (5.02, 6.39)\n5.44 (4.66, 6.08)\n0.062\n\n\nhf_ln\n153\n5.18 (4.57, 5.96)\n5.55 (4.70, 6.19)\n4.90 (4.23, 5.55)\n0.005**\n\n\nage\n153\n51 (44, 58)\n51 (45, 58)\n49 (43, 57)\n0.321\n\n\ntbw\n153\n40 (35, 48)\n37 (32, 43)\n43 (37, 51)\n&lt;0.001***\n\n\nicw\n153\n24.5 (21.3, 29.6)\n22.6 (19.8, 26.6)\n26.4 (23.0, 31.2)\n&lt;0.001***\n\n\necw\n153\n14.9 (13.0, 18.2)\n13.9 (12.2, 16.6)\n16.7 (14.3, 19.3)\n&lt;0.001***\n\n\nprotein\n153\n10.60 (9.20, 12.70)\n9.80 (8.60, 11.55)\n11.40 (10.00, 13.50)\n&lt;0.001***\n\n\nminerals\n153\n3.83 (3.26, 4.57)\n3.55 (3.13, 4.15)\n4.11 (3.51, 4.81)\n&lt;0.001***\n\n\nbfm\n153\n33 (26, 43)\n29 (24, 37)\n38 (29, 49)\n&lt;0.001***\n\n\nslm\n153\n51 (45, 61)\n47 (41, 55)\n55 (48, 65)\n&lt;0.001***\n\n\nffm\n153\n54 (47, 65)\n50 (43, 59)\n59 (51, 69)\n&lt;0.001***\n\n\nsmm\n153\n30 (26, 37)\n28 (24, 33)\n32 (28, 39)\n&lt;0.001***\n\n\nbmi\n153\n30.6 (28.6, 35.2)\n28.9 (27.2, 31.4)\n33.2 (30.2, 38.8)\n&lt;0.001***\n\n\npbf\n153\n39 (33, 44)\n38 (33, 43)\n40 (33, 47)\n0.351\n\n\nlean_mass_of_right_arm\n153\n3.02 (2.45, 3.77)\n2.72 (2.24, 3.23)\n3.35 (2.91, 3.95)\n&lt;0.001***\n\n\nlean_mass_percent_of_right_arm\n153\n109 (102, 117)\n107 (100, 114)\n113 (105, 121)\n0.003**\n\n\nlean_mass_of_left_arm\n153\n2.97 (2.45, 3.72)\n2.69 (2.22, 3.25)\n3.28 (2.82, 3.98)\n&lt;0.001***\n\n\nlean_mass_percent_of_left_arm\n153\n109 (101, 116)\n106 (98, 114)\n112 (104, 118)\n0.003**\n\n\nlean_mass_of_trunk\n153\n24.5 (20.9, 28.8)\n22.9 (19.8, 26.0)\n26.5 (23.6, 30.5)\n&lt;0.001***\n\n\nlean_mass_percent_of_trunk\n153\n103.7 (99.7, 108.0)\n102.6 (98.5, 106.6)\n105.5 (100.4, 109.1)\n0.011*\n\n\nlean_mass_of_right_leg\n153\n7.90 (6.62, 9.80)\n7.42 (6.37, 8.93)\n8.88 (7.41, 10.13)\n&lt;0.001***\n\n\nlean_mass_percent_of_right_leg\n153\n97 (92, 103)\n95 (91, 102)\n99 (93, 103)\n0.090\n\n\nlean_mass_of_left_leg\n153\n7.89 (6.63, 9.81)\n7.38 (6.27, 8.97)\n8.82 (7.40, 10.09)\n&lt;0.001***\n\n\nlean_mass_percent_of_left_leg\n153\n97 (92, 102)\n96 (90, 101)\n98 (93, 103)\n0.069\n\n\ntbw_of_right_arm\n153\n2.34 (1.91, 2.94)\n2.12 (1.74, 2.51)\n2.61 (2.26, 3.07)\n&lt;0.001***\n\n\ntbw_of_left_arm\n153\n2.32 (1.91, 2.90)\n2.10 (1.73, 2.53)\n2.55 (2.20, 3.10)\n&lt;0.001***\n\n\ntbw_of_trunk\n153\n19.0 (16.3, 22.5)\n17.8 (15.4, 20.3)\n20.7 (18.4, 23.7)\n&lt;0.001***\n\n\ntbw_of_right_leg\n153\n6.19 (5.15, 7.65)\n5.78 (4.96, 6.95)\n6.92 (5.77, 7.88)\n&lt;0.001***\n\n\ntbw_of_left_leg\n153\n6.16 (5.16, 7.66)\n5.74 (4.88, 6.98)\n6.87 (5.80, 7.85)\n&lt;0.001***\n\n\nicw_of_right_arm\n153\n1.46 (1.19, 1.82)\n1.32 (1.08, 1.56)\n1.62 (1.40, 1.91)\n&lt;0.001***\n\n\nicw_of_left_arm\n153\n1.43 (1.18, 1.80)\n1.30 (1.06, 1.57)\n1.59 (1.37, 1.93)\n&lt;0.001***\n\n\nicw_of_trunk\n153\n11.80 (10.10, 13.90)\n11.00 (9.55, 12.60)\n12.70 (11.30, 14.80)\n&lt;0.001***\n\n\nicw_of_right_leg\n153\n3.80 (3.21, 4.73)\n3.57 (3.06, 4.33)\n4.27 (3.55, 4.93)\n&lt;0.001***\n\n\nicw_of_left_leg\n153\n3.83 (3.20, 4.73)\n3.57 (3.03, 4.37)\n4.25 (3.55, 4.90)\n&lt;0.001***\n\n\necw_of_right_arm\n153\n0.88 (0.72, 1.12)\n0.80 (0.65, 0.95)\n0.99 (0.83, 1.16)\n&lt;0.001***\n\n\necw_of_left_arm\n153\n0.88 (0.72, 1.09)\n0.79 (0.65, 0.96)\n0.98 (0.83, 1.17)\n&lt;0.001***\n\n\necw_of_trunk\n153\n7.20 (6.20, 8.60)\n6.70 (5.90, 7.85)\n7.80 (7.00, 9.20)\n&lt;0.001***\n\n\necw_of_right_leg\n153\n2.39 (1.98, 2.89)\n2.19 (1.87, 2.64)\n2.61 (2.19, 3.00)\n&lt;0.001***\n\n\necw_of_left_leg\n153\n2.39 (2.00, 2.91)\n2.19 (1.88, 2.64)\n2.63 (2.20, 2.97)\n&lt;0.001***\n\n\necw_tbw_ratio\n153\n0.381 (0.377, 0.386)\n0.381 (0.377, 0.386)\n0.381 (0.377, 0.387)\n0.609\n\n\necw_tbw_ratio_of_right_arm\n153\n0.378 (0.375, 0.381)\n0.378 (0.375, 0.381)\n0.379 (0.376, 0.381)\n0.220\n\n\necw_tbw_ratio_of_left_arm\n153\n0.380 (0.377, 0.382)\n0.379 (0.376, 0.382)\n0.380 (0.378, 0.382)\n0.201\n\n\necw_tbw_ratio_of_trunk\n153\n0.381 (0.377, 0.386)\n0.382 (0.377, 0.386)\n0.381 (0.377, 0.385)\n0.826\n\n\necw_tbw_ratio_of_right_leg\n153\n0.381 (0.376, 0.388)\n0.381 (0.376, 0.387)\n0.382 (0.376, 0.388)\n0.434\n\n\necw_tbw_ratio_of_left_leg\n153\n0.382 (0.377, 0.388)\n0.382 (0.377, 0.387)\n0.383 (0.376, 0.389)\n0.406\n\n\nbfm_of_right_arm\n153\n2.60 (1.90, 3.90)\n2.15 (1.70, 3.20)\n3.20 (2.10, 4.90)\n&lt;0.001***\n\n\nbfm_percent_of_right_arm\n153\n315 (233, 530)\n265 (209, 348)\n432 (292, 647)\n&lt;0.001***\n\n\nbfm_of_left_arm\n153\n2.70 (1.90, 3.90)\n2.15 (1.75, 3.25)\n3.30 (2.10, 5.00)\n&lt;0.001***\n\n\nbfm_percent_of_left_arm\n153\n322 (239, 536)\n271 (209, 351)\n438 (299, 643)\n&lt;0.001***\n\n\nbfm_of_trunk\n153\n17.4 (13.6, 21.9)\n15.1 (12.9, 19.2)\n19.3 (15.7, 24.0)\n&lt;0.001***\n\n\nbfm_percent_of_trunk\n153\n341 (284, 454)\n302 (261, 352)\n400 (330, 488)\n&lt;0.001***\n\n\nbfm_of_right_leg\n153\n4.60 (3.60, 5.90)\n3.90 (3.40, 5.20)\n4.90 (4.10, 6.40)\n0.001**\n\n\nbfm_percent_of_right_leg\n153\n207 (176, 276)\n188 (166, 219)\n242 (197, 304)\n&lt;0.001***\n\n\nbfm_of_left_leg\n153\n4.60 (3.60, 5.90)\n3.90 (3.40, 5.20)\n4.80 (4.10, 6.50)\n0.001**\n\n\nbfm_percent_of_left_leg\n153\n207 (176, 276)\n189 (164, 218)\n242 (195, 305)\n&lt;0.001***\n\n\ninbody_score\n153\n66 (59, 71)\n67 (62, 72)\n65 (56, 71)\n0.061\n\n\ntarget_weight\n153\n69 (61, 78)\n65 (57, 74)\n74 (66, 83)\n&lt;0.001***\n\n\nweight_control\n153\n-20 (-29, -13)\n-15 (-23, -11)\n-24 (-34, -16)\n&lt;0.001***\n\n\nbfm_control\n153\n-20 (-29, -13)\n-15 (-23, -12)\n-24 (-34, -16)\n&lt;0.001***\n\n\nffm_control\n153\n\n\n\n\n\n\n0.250\n\n\n    0\n\n\n143 (93%)\n67 (88%)\n76 (99%)\n\n\n\n\n    0.2\n\n\n2 (1.3%)\n2 (2.6%)\n0 (0%)\n\n\n\n\n    0.3\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    0.4\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    0.8\n\n\n2 (1.3%)\n1 (1.3%)\n1 (1.3%)\n\n\n\n\n    1.5\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    2\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    3.7\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    6.3\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\nbmr\n153\n1,535 (1,386, 1,766)\n1,453 (1,309, 1,635)\n1,634 (1,465, 1,861)\n&lt;0.001***\n\n\nwhr\n153\n0.99 (0.93, 1.03)\n0.96 (0.92, 1.01)\n1.02 (0.96, 1.07)\n&lt;0.001***\n\n\nvfa\n153\n160 (123, 213)\n142 (115, 189)\n185 (137, 231)\n&lt;0.001***\n\n\nobesity_degree\n153\n145 (132, 164)\n136 (128, 150)\n154 (141, 182)\n&lt;0.001***\n\n\nbcm\n153\n35 (31, 42)\n32 (28, 38)\n38 (33, 45)\n&lt;0.001***\n\n\nac\n153\n35.9 (33.9, 39.3)\n34.3 (32.5, 36.3)\n37.9 (35.6, 42.1)\n&lt;0.001***\n\n\namc\n153\n29.6 (27.8, 32.3)\n28.3 (27.3, 30.0)\n31.4 (29.3, 33.2)\n&lt;0.001***\n\n\nbmc\n153\n3.18 (2.74, 3.77)\n2.98 (2.61, 3.45)\n3.46 (2.88, 3.96)\n&lt;0.001***\n\n\ntbw_ffm_ratio\n153\n73.30 (73.10, 73.50)\n73.20 (73.10, 73.40)\n73.30 (73.20, 73.60)\n0.003**\n\n\nffmi\n153\n19.80 (17.70, 21.40)\n18.40 (16.85, 20.25)\n20.40 (19.50, 22.10)\n&lt;0.001***\n\n\nfmi\n153\n12.0 (9.3, 15.0)\n10.8 (8.8, 13.3)\n12.9 (10.3, 18.1)\n0.005**\n\n\nkhz_ra_5_phase_angle\n153\n2.60 (2.20, 2.80)\n2.40 (2.10, 2.70)\n2.60 (2.40, 2.90)\n0.001**\n\n\nkhz_la_5_phase_angle\n153\n2.40 (2.10, 2.70)\n2.40 (2.10, 2.70)\n2.50 (2.30, 2.80)\n0.018*\n\n\nkhz_tr_5_phase_angle\n153\n3.30 (2.80, 3.80)\n3.30 (2.95, 3.85)\n3.40 (2.70, 3.70)\n0.608\n\n\nkhz_rl_5_phase_angle\n153\n2.60 (2.40, 2.90)\n2.50 (2.30, 2.80)\n2.70 (2.50, 2.90)\n0.044*\n\n\nkhz_ll_5_phase_angle\n153\n2.60 (2.30, 2.80)\n2.50 (2.20, 2.85)\n2.70 (2.40, 2.80)\n0.031*\n\n\nkhz_ra_50_phase_angle\n153\n5.20 (4.90, 5.60)\n5.20 (4.70, 5.50)\n5.30 (5.00, 5.80)\n0.046*\n\n\nkhz_la_50_phase_angle\n153\n5.00 (4.70, 5.40)\n4.90 (4.60, 5.35)\n5.10 (4.80, 5.60)\n0.029*\n\n\nkhz_tr_50_phase_angle\n153\n7.40 (6.80, 8.10)\n7.20 (6.60, 8.10)\n7.50 (7.00, 8.10)\n0.057\n\n\nkhz_rl_50_phase_angle\n153\n5.70 (5.20, 6.30)\n5.65 (5.15, 6.25)\n5.80 (5.30, 6.30)\n0.395\n\n\nkhz_ll_50_phase_angle\n153\n5.60 (5.20, 6.20)\n5.60 (5.05, 6.10)\n5.70 (5.30, 6.30)\n0.214\n\n\nkhz_ra_250_phase_angle\n153\n4.80 (4.50, 5.00)\n4.70 (4.40, 4.90)\n4.80 (4.60, 5.10)\n0.013*\n\n\nkhz_la_250_phase_angle\n153\n4.50 (4.30, 4.80)\n4.45 (4.20, 4.80)\n4.60 (4.40, 4.90)\n0.044*\n\n\nkhz_tr_250_phase_angle\n153\n7.60 (7.00, 8.30)\n7.60 (7.00, 8.25)\n7.60 (6.80, 8.30)\n0.977\n\n\nkhz_rl_250_phase_angle\n153\n4.40 (4.10, 4.60)\n4.35 (4.10, 4.60)\n4.40 (4.20, 4.70)\n0.431\n\n\nkhz_ll_250_phase_angle\n153\n4.60 (4.30, 4.80)\n4.50 (4.30, 4.80)\n4.60 (4.30, 4.90)\n0.360\n\n\nKhz_50_whole_body_phase_angle\n153\n5.50 (5.10, 6.00)\n5.45 (4.90, 5.90)\n5.60 (5.30, 6.10)\n0.086\n\n\nmeasured_circumference_of_neck\n153\n39.4 (37.0, 42.5)\n38.0 (35.8, 40.0)\n41.3 (38.4, 44.3)\n&lt;0.001***\n\n\nmeasured_circumference_of_chest\n153\n106 (101, 114)\n103 (98, 107)\n112 (105, 117)\n&lt;0.001***\n\n\nmeasured_circumference_of_abdomen\n153\n105 (96, 120)\n98 (94, 110)\n113 (103, 124)\n&lt;0.001***\n\n\nmeasured_circumference_of_hip\n153\n107 (103, 114)\n104 (100, 109)\n112 (106, 118)\n&lt;0.001***\n\n\nmeasured_circumference_of_right_arm\n153\n36.1 (34.0, 39.7)\n34.8 (32.7, 36.4)\n38.2 (36.0, 42.5)\n&lt;0.001***\n\n\nmeasured_circumference_of_left_arm\n153\n35.9 (33.9, 39.3)\n34.3 (32.5, 36.3)\n37.9 (35.6, 42.1)\n&lt;0.001***\n\n\nmeasured_circumference_of_right_thigh\n153\n58.6 (55.7, 62.2)\n56.5 (53.5, 60.5)\n60.5 (57.6, 63.4)\n&lt;0.001***\n\n\nmeasured_circumference_of_left_thigh\n153\n58.6 (55.5, 62.4)\n56.4 (53.5, 60.7)\n60.3 (57.5, 63.4)\n&lt;0.001***\n\n\ninbody_type\n153\n\n\n\n\n\n\n\n\n\n\n    970\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nsmi\n153\n8.00 (7.10, 8.80)\n7.45 (6.85, 8.20)\n8.50 (7.90, 9.20)\n&lt;0.001***\n\n\nsmi_t_score\n153\n0.30 (-0.30, 1.20)\n-0.05 (-0.65, 0.95)\n0.60 (0.00, 1.40)\n&lt;0.001***\n\n\nsmi_z_score\n153\n0.30 (-0.40, 1.10)\n0.00 (-0.70, 0.80)\n0.50 (0.00, 1.30)\n0.001**\n\n\nwhole_body_ecw_tbw_ratio_t_score\n153\n1.10 (0.30, 2.10)\n1.10 (0.10, 1.90)\n1.10 (0.60, 2.20)\n0.121\n\n\nwhole_body_ecw_tbw_ratio_z_score\n153\n0.20 (-0.40, 1.00)\n0.10 (-0.55, 0.90)\n0.40 (-0.20, 1.20)\n0.047*\n\n\nvfa_t_score\n153\n2.40 (1.40, 3.80)\n1.70 (1.10, 2.95)\n3.20 (1.90, 4.20)\n&lt;0.001***\n\n\nvfa_z_score\n153\n1.20 (0.40, 2.40)\n0.80 (0.30, 1.70)\n2.10 (0.90, 3.00)\n&lt;0.001***\n\n\nbmi_t_score\n153\n1.10 (0.60, 2.20)\n0.70 (0.35, 1.30)\n1.70 (1.00, 2.90)\n&lt;0.001***\n\n\nbmi_z_score\n153\n0.70 (0.10, 1.70)\n0.20 (-0.10, 0.95)\n1.10 (0.60, 2.30)\n&lt;0.001***\n\n\nsubcutaneous_fat\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\narms_legs_fat_ratio\n153\n15 (11, 20)\n12 (10, 17)\n16 (12, 23)\n&lt;0.001***\n\n\nvisceral_fat\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nabdominal_fat\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nv_s_ratio\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nsfa\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nwhtr\n153\n0.63 (0.58, 0.69)\n0.60 (0.57, 0.65)\n0.66 (0.61, 0.73)\n&lt;0.001***\n\n\nbai\n153\n31.4 (28.5, 35.4)\n31.0 (28.1, 33.9)\n31.7 (29.2, 37.0)\n0.077\n\n\nabsi\n153\n0.081 (0.079, 0.084)\n0.081 (0.078, 0.084)\n0.082 (0.079, 0.084)\n0.319\n\n\nconicity_index\n153\n1.35 (1.28, 1.40)\n1.32 (1.27, 1.37)\n1.37 (1.31, 1.41)\n&lt;0.001***\n\n\nsvr\n153\n0.18 (0.14, 0.24)\n0.18 (0.15, 0.24)\n0.18 (0.13, 0.24)\n0.632\n\n\nkhz_50_ab_impedance\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nkhz_250_ab_impedance\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nwc\n153\n105 (96, 120)\n98 (94, 110)\n113 (103, 124)\n&lt;0.001***\n\n\nangle_r\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nangle_l\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nsmm_wt_ratio\n153\n33.7 (30.8, 37.2)\n33.8 (31.4, 37.2)\n33.6 (29.4, 37.3)\n0.638\n\n\nbfm_percent_of_whole_body\n153\n333 (266, 429)\n296 (250, 367)\n374 (284, 520)\n&lt;0.001***\n\n\necm_bcm_ratio\n153\n0.538 (0.529, 0.548)\n0.540 (0.529, 0.550)\n0.537 (0.529, 0.547)\n0.599\n\n\ntbw_wt_ratio\n153\n45 (41, 49)\n45 (42, 49)\n44 (39, 49)\n0.379\n\n\nbcm_t_score\n153\n0.10 (-0.50, 0.90)\n-0.10 (-0.65, 0.70)\n0.30 (-0.30, 1.10)\n0.021*\n\n\nbcm_z_score\n153\n0.40 (-0.30, 1.30)\n0.10 (-0.40, 1.15)\n0.60 (0.00, 1.30)\n0.019*\n\n\nffmi_t_score\n153\n0.50 (-0.40, 1.20)\n0.00 (-0.50, 1.00)\n0.80 (0.10, 1.60)\n&lt;0.001***\n\n\nffmi_z_score\n153\n0.50 (-0.40, 1.30)\n0.00 (-0.50, 1.00)\n0.80 (0.10, 1.60)\n0.003**\n\n\nfmi_t_score\n153\n1.30 (0.70, 2.60)\n0.95 (0.50, 1.40)\n1.90 (1.20, 3.10)\n&lt;0.001***\n\n\nfmi_z_score\n153\n0.80 (0.20, 1.90)\n0.40 (0.00, 0.85)\n1.30 (0.50, 2.30)\n&lt;0.001***\n\n\npbf_t_score\n153\n1.40 (0.80, 2.00)\n1.10 (0.65, 1.50)\n1.80 (1.20, 2.30)\n&lt;0.001***\n\n\npbf_z_score\n153\n0.80 (0.30, 1.60)\n0.60 (0.10, 1.00)\n1.20 (0.60, 1.80)\n&lt;0.001***\n\n\nweight_t_score\n153\n1.10 (0.20, 2.00)\n0.60 (0.10, 1.60)\n1.50 (0.70, 2.60)\n&lt;0.001***\n\n\nweight_z_score\n153\n0.60 (0.00, 1.70)\n0.20 (-0.30, 1.15)\n1.10 (0.40, 2.10)\n&lt;0.001***\n\n\nwhr_t_score\n153\n1.10 (0.30, 1.70)\n0.70 (0.20, 1.40)\n1.40 (0.60, 1.90)\n&lt;0.001***\n\n\nwhr_z_score\n153\n0.50 (-0.10, 1.10)\n0.30 (-0.30, 0.80)\n0.80 (0.20, 1.30)\n&lt;0.001***\n\n\nkhz_whole_body_phase_angle_t_score\n153\n-0.70 (-1.50, -0.10)\n-0.80 (-1.50, -0.10)\n-0.70 (-1.50, -0.10)\n0.953\n\n\nkhz_whole_body_phase_angle_z_score\n153\n-0.10 (-1.00, 0.60)\n-0.10 (-1.00, 0.70)\n-0.10 (-1.00, 0.40)\n0.745\n\n\ntbw_wt_ratio_t_score\n153\n-1.40 (-2.00, -0.80)\n-1.10 (-1.50, -0.60)\n-1.80 (-2.30, -1.20)\n&lt;0.001***\n\n\ntbw_wt_ratio_z_score\n153\n-0.80 (-1.50, -0.30)\n-0.60 (-1.00, -0.15)\n-1.20 (-1.80, -0.60)\n&lt;0.001***\n\n\nsmm_wt_ratio_t_score\n153\n-1.40 (-2.00, -0.80)\n-1.10 (-1.50, -0.70)\n-1.70 (-2.20, -1.20)\n&lt;0.001***\n\n\nsmm_wt_ratio_z_score\n153\n-0.80 (-1.60, -0.30)\n-0.60 (-1.00, -0.15)\n-1.30 (-1.80, -0.60)\n&lt;0.001***\n\n\necm_bcm_ratio_t_score\n153\n1.00 (0.10, 1.80)\n1.00 (-0.10, 1.75)\n0.90 (0.20, 1.90)\n0.347\n\n\necm_bcm_ratio_z_score\n153\n0.20 (-0.60, 1.00)\n0.30 (-0.65, 0.75)\n0.10 (-0.50, 1.20)\n0.305\n\n\nr_ht_ratio\n153\n335 (283, 380)\n369 (317, 409)\n306 (271, 340)\n&lt;0.001***\n\n\nxc_ht_ratio\n153\n32.4 (28.6, 35.8)\n34.2 (30.8, 38.2)\n30.8 (26.3, 33.4)\n&lt;0.001***\n\n\n\nP-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#medication-information",
    "href": "eda2.html#medication-information",
    "title": "Data Processing & EDA",
    "section": "Medication Information",
    "text": "Medication Information\n\n\n\n\n\n\nMedication Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nMedication Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~60)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nAntihypertensives\n153\n\n\n\n\n0.034*\n\n\n    No\n\n\n65 (86%)\n55 (71%)\n\n\n\n\n    Yes\n\n\n11 (14%)\n22 (29%)\n\n\n\n\nHyperlipidemias\n153\n\n\n\n\n0.789\n\n\n    No\n\n\n65 (86%)\n67 (87%)\n\n\n\n\n    Yes\n\n\n11 (14%)\n10 (13%)\n\n\n\n\nAntidepressants\n153\n\n\n\n\n0.088\n\n\n    No\n\n\n66 (87%)\n73 (95%)\n\n\n\n\n    Yes\n\n\n10 (13%)\n4 (5.2%)\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%)\n\n\n2 Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#dietary-information",
    "href": "eda2.html#dietary-information",
    "title": "Data Processing & EDA",
    "section": "Dietary Information",
    "text": "Dietary Information\n\nMediterranean Diet Adherence Screener (MEDAS)\n14-item Mediterranean Diet Adherence Screener (MEDAS):\nIt is a short questionnaire used to assess how well someone is following the Mediterranean Diet. It includes 14 questions, each of which gives 1 point if the relevant criterion is met.\n\n0–5 points → Low compliance\n6–9 points → Moderate compliance\n10–14 points → High compliance\n\nThe higher the score, the greater the adherence to the Mediterranean Diet and the more likely its health benefits, especially in cardiovascular prevention.\n\n\n\n\n\n\n\n\nFigure 4: Distribution of MEDAS Score\n\n\n\n\n\n\n\nHealthy Eating Index (HEI)\n\n\n\n\n\n\n\n\nFigure 5: Distribution of HEI Scores (Healthy Eating Index)\n\n\n\n\n\n\n\nDietary Inflammatory Index (DII)\n\n\n\n\n\n\n\n\nFigure 6: Distribution of DII Scores (Dietary Inflammatory Index)\n\n\n\n\n\n\n\n\n\n\n\nDietary Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nDietary Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~60)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nMEDAS_Score\n153\n6.00 (5.00, 7.00)\n6.00 (5.00, 7.00)\n0.331\n\n\nTotal_Score\n150\n61 (40, 67)\n66 (56, 71)\n0.007**\n\n\n    Missing\n\n\n2\n1\n\n\n\n\nTotal_DII\n150\n2.29 (2.21, 2.54)\n2.29 (1.85, 2.59)\n0.355\n\n\n    Missing\n\n\n2\n1\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nMissing values are due to IDs existing in the MEDAS score data but not in the other two dietary indices.",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#activity-tracker",
    "href": "eda2.html#activity-tracker",
    "title": "Data Processing & EDA",
    "section": "Activity Tracker",
    "text": "Activity Tracker\n\n\n\n\n\n\nActivity Tracker Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nActivity Tracker Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~60)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nSteps\n147\n6,982 (5,156, 9,107)\n7,497 (4,969, 9,537)\n0.542\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nSleep\n147\n5.81 (4.83, 6.92)\n5.62 (4.76, 6.88)\n0.552\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nSedentary\n147\n10.13 (8.41, 11.42)\n10.14 (9.10, 11.66)\n0.362\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nLight\n147\n2.40 (2.00, 2.89)\n2.30 (1.96, 2.76)\n0.537\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nModerate\n147\n1.89 (1.38, 2.41)\n1.99 (1.52, 2.48)\n0.360\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nVigorous\n147\n0.01 (0.00, 0.03)\n0.01 (0.00, 0.03)\n0.720\n\n\n    Missing\n\n\n2\n4\n\n\n\n\n\nTimes are in hours. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nIDs do not fully match other data i.e. missing",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#smoking-status",
    "href": "eda2.html#smoking-status",
    "title": "Data Processing & EDA",
    "section": "Smoking Status",
    "text": "Smoking Status\n\n\n\n\n\n\nSmoking Status (Timepoint 1)\n\n\n\n\n\n\n\n\n\nSmoking Status Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~60)\n\np-value2,3\n\n\nNO\nN = 741\nYES\nN = 771\n\n\n\n\nSmoking_Status\n151\n\n\n\n\n0.218\n\n\n    Current smoker\n\n\n18 (24%)\n15 (19%)\n\n\n\n\n    Former smoker\n\n\n19 (26%)\n30 (39%)\n\n\n\n\n    Never smoked\n\n\n37 (50%)\n32 (42%)\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%)\n\n\n2 Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nIDs do not fully match other data i.e. missing",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#targeted-metabolites",
    "href": "eda2.html#targeted-metabolites",
    "title": "Data Processing & EDA",
    "section": "Targeted Metabolites",
    "text": "Targeted Metabolites\n\nAmino Acids & Sugars\n\n\n\n\n\n\nSugar & Amino Acid Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nSugar & Amino Acid Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~60)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nAnhydroglucitol\n153\n100 (78, 134)\n91 (73, 115)\n0.051\n\n\nGlucose\n153\n6,430 (4,757, 7,614)\n7,229 (5,311, 7,887)\n0.115\n\n\nMannose\n153\n45 (31, 59)\n55 (35, 68)\n0.039*\n\n\nFructose\n153\n22 (6, 28)\n21 (6, 32)\n0.418\n\n\nValine\n153\n214 (154, 270)\n251 (184, 325)\n0.010**\n\n\nLeucine\n153\n184 (146, 231)\n226 (177, 270)\n0.006**\n\n\nIsoleucine\n153\n55 (39, 72)\n69 (52, 87)\n0.008**\n\n\nGlutamine\n153\n583 (427, 710)\n566 (388, 692)\n0.692\n\n\nGlutamic_Acid\n153\n46 (28, 73)\n76 (43, 119)\n&lt;0.001***\n\n\nPhenylalanine\n153\n66 (54, 74)\n71 (60, 85)\n0.021*\n\n\nTyrosine\n153\n64 (46, 79)\n70 (49, 88)\n0.072\n\n\nTryptophan\n153\n50 (35, 59)\n53 (38, 63)\n0.480\n\n\nGlutamine_To_Glutamic_Acid_Ratio\n153\n12 (9, 20)\n7 (5, 12)\n&lt;0.001***\n\n\nBCAA_To_AAA_Ratio\n153\n2.67 (2.31, 2.93)\n2.72 (2.39, 3.08)\n0.116\n\n\n\nUnits are in μΜ. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\nAcylCarnitines\n\n\n\n\n\n\nAcylCarnitines Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nAcylCarnitines Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~60)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nAcetylcarnitine\n153\n10.0 (7.1, 14.9)\n9.9 (7.2, 12.9)\n0.903\n\n\nPropionylcarnitine\n153\n0.59 (0.46, 0.72)\n0.57 (0.40, 0.77)\n0.822\n\n\nButyrylcarnitine\n153\n0.09 (0.07, 0.12)\n0.09 (0.06, 0.14)\n0.964\n\n\nValerylcarnitine\n153\n0.055 (0.036, 0.071)\n0.056 (0.036, 0.065)\n0.758\n\n\nHexanoylcarnitine\n153\n0.06 (0.04, 0.07)\n0.05 (0.04, 0.07)\n0.398\n\n\nOctanoylcarnitine\n153\n0.14 (0.09, 0.18)\n0.14 (0.09, 0.22)\n0.865\n\n\nDecanoylcarnitine\n153\n0.26 (0.18, 0.33)\n0.25 (0.18, 0.36)\n0.881\n\n\nLauroylcarnitine\n153\n0.04 (0.03, 0.06)\n0.04 (0.03, 0.06)\n0.430\n\n\nMyristoylcarnitine\n153\n0.018 (0.014, 0.024)\n0.020 (0.015, 0.027)\n0.398\n\n\nPalmitoylcarnitine\n153\n0.10 (0.08, 0.12)\n0.10 (0.08, 0.12)\n0.874\n\n\nStearoylcarnitine\n153\n0.019 (0.013, 0.025)\n0.020 (0.012, 0.026)\n0.361\n\n\nLinoleoylcarnitine\n153\n0.07 (0.05, 0.09)\n0.08 (0.05, 0.10)\n0.673\n\n\nOleoylcarnitine\n153\n0.13 (0.09, 0.18)\n0.13 (0.10, 0.18)\n0.763\n\n\n\nUnits are in μΜ. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#urine",
    "href": "eda2.html#urine",
    "title": "Data Processing & EDA",
    "section": "Urine",
    "text": "Urine\n\nHILIC Panel\n\n\n\n\n\n\nHILIC Urine Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nHILIC Urine Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 751\nYES\nN = 771\n\n\n\n\n2_Hydroxyisovalericacid\n152\n3,185 (2,455, 5,608)\n3,016 (2,399, 4,103)\n0.413\n\n\n2_Hydroxyisovalericacid_Detected\n152\n63 (84%)\n64 (83%)\n0.883\n\n\n3_Methylhistidine\n152\n348,620 (197,629, 806,731)\n302,983 (186,644, 603,264)\n0.603\n\n\n3_Methylhistidine_Detected\n152\n68 (91%)\n75 (97%)\n0.096\n\n\nAcetylcarnitine\n152\n2,204,225 (986,349, 4,752,079)\n2,019,176 (1,067,740, 3,042,715)\n0.221\n\n\nAdenine\n152\n26,812 (19,776, 49,079)\n22,824 (16,797, 31,158)\n0.051\n\n\nAdenine_Detected\n152\n33 (44%)\n27 (35%)\n0.260\n\n\nAlanine\n152\n37,730 (21,290, 88,226)\n37,226 (23,986, 54,962)\n0.802\n\n\nAlanine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nAllantoin\n152\n10,206 (6,164, 16,144)\n7,824 (4,728, 13,724)\n0.115\n\n\nAscorbic_Acid\n152\n1,681 (1,170, 2,260)\n1,659 (1,456, 2,105)\n0.645\n\n\nAscorbic_Acid_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nAsparagine\n152\n6,143 (4,686, 22,452)\n5,498 (3,823, 8,695)\n0.059\n\n\nBenzoic_Acid\n152\n1,033 (466, 1,971)\n1,037 (529, 1,830)\n0.710\n\n\nBenzoic_Acid_Detected\n152\n38 (51%)\n33 (43%)\n0.335\n\n\nBetaine\n152\n1,084,335 (749,304, 2,106,365)\n995,191 (695,102, 1,849,974)\n0.771\n\n\nCaffeine\n152\n19,918 (7,070, 51,437)\n29,444 (11,627, 45,840)\n0.505\n\n\nCaffeine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nCholine\n152\n233,933 (143,675, 380,375)\n223,304 (148,047, 327,457)\n0.672\n\n\nCotinine\n152\n57,760 (3,080, 311,788)\n83,105 (805, 278,217)\n0.514\n\n\nCotinine_Detected\n152\n40 (53%)\n49 (64%)\n0.197\n\n\nCreatine\n152\n562,595 (327,032, 1,404,337)\n471,766 (275,121, 1,515,620)\n0.828\n\n\nCreatinine\n152\n46,890,019 (38,750,408, 64,798,358)\n48,216,574 (42,130,912, 55,874,614)\n0.880\n\n\nCytosine\n152\n22,015 (12,702, 45,733)\n15,288 (11,561, 30,337)\n0.070\n\n\nCytosine_Detected\n152\n59 (79%)\n64 (83%)\n0.485\n\n\nDimethylamine\n152\n35,887 (27,306, 58,679)\n36,599 (30,851, 44,130)\n0.950\n\n\nGlutamic_Acid\n152\n651 (521, 1,516)\n637 (487, 883)\n0.258\n\n\nGlutamic_Acid_Detected\n152\n43 (57%)\n35 (45%)\n0.143\n\n\nGlutamine\n152\n218,368 (165,371, 383,342)\n195,728 (141,605, 295,039)\n0.078\n\n\nGuanine\n152\n1,626 (912, 2,972)\n1,741 (981, 2,849)\n0.854\n\n\nGuanine_Detected\n152\n69 (92%)\n75 (97%)\n0.164\n\n\nHippuric_Acid\n152\n95,381 (45,723, 150,073)\n70,156 (35,912, 118,589)\n0.032*\n\n\nHistamine\n152\n3,539 (2,178, 8,294)\n2,667 (1,950, 4,754)\n0.022*\n\n\nHistamine_Detected\n152\n53 (71%)\n52 (68%)\n0.676\n\n\nHypotaurine\n152\n248 (186, 618)\n235 (192, 318)\n0.553\n\n\nHypotaurine_Detected\n152\n25 (33%)\n23 (30%)\n0.646\n\n\nHypoxanthine\n152\n84,144 (57,252, 129,257)\n86,775 (57,836, 123,000)\n0.560\n\n\nHypoxanthine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nIndole_3_Lactic_Acid\n152\n2,695 (2,011, 3,676)\n2,732 (2,233, 3,262)\n0.909\n\n\nInosine\n152\n1,363 (751, 2,847)\n1,190 (710, 2,085)\n0.197\n\n\nInosine_Detected\n152\n72 (96%)\n75 (97%)\n0.679\n\n\nKynurenate\n152\n20,024 (12,965, 30,800)\n15,983 (11,157, 24,714)\n0.134\n\n\nLactose\n152\n1,938 (1,168, 6,823)\n1,497 (899, 4,382)\n0.055\n\n\nLysine\n152\n20,792 (11,267, 71,657)\n15,306 (9,869, 36,877)\n0.063\n\n\nLysine_Detected\n152\n58 (77%)\n70 (91%)\n0.022*\n\n\nMannitol\n152\n1,640 (645, 3,638)\n1,400 (837, 3,390)\n0.962\n\n\nMannitol_Detected\n152\n69 (92%)\n69 (90%)\n0.611\n\n\nMethylamine\n152\n6,225 (4,364, 9,510)\n6,885 (4,534, 8,616)\n0.900\n\n\nMethylamine_Detected\n152\n74 (99%)\n77 (100%)\n0.493\n\n\nMonoisoamylamine\n152\n17,860 (11,138, 28,966)\n14,713 (11,073, 22,660)\n0.227\n\n\nMonoisoamylamine_Detected\n152\n72 (96%)\n73 (95%)\n&gt;0.999\n\n\nNicotinamide\n152\n1,824 (1,206, 2,467)\n1,984 (1,489, 2,621)\n0.073\n\n\nNicotinamide_Detected\n152\n73 (97%)\n77 (100%)\n0.242\n\n\nPantothenate\n152\n11,335 (6,093, 27,118)\n7,450 (3,593, 16,475)\n0.036*\n\n\nPhenylalanine\n152\n48,848 (24,249, 86,924)\n44,872 (32,768, 75,309)\n0.924\n\n\nPyridoxine\n152\n42,271 (25,182, 84,688)\n31,014 (24,349, 63,323)\n0.166\n\n\nPyridoxine_Detected\n152\n33 (44%)\n24 (31%)\n0.102\n\n\nPyroglutamic\n152\n36,467 (22,572, 111,137)\n35,772 (20,881, 51,279)\n0.227\n\n\nPyroglutamic_Detected\n152\n71 (95%)\n72 (94%)\n&gt;0.999\n\n\nRivoflavine\n152\n2,300 (809, 5,971)\n1,339 (693, 3,181)\n0.128\n\n\nRivoflavine_Detected\n152\n59 (79%)\n61 (79%)\n0.933\n\n\nSerine\n152\n22,481 (16,681, 75,333)\n20,308 (15,709, 28,845)\n0.180\n\n\nSorbitol\n152\n728 (424, 1,258)\n669 (428, 1,297)\n0.894\n\n\nSorbitol_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nSucrose\n152\n301 (170, 478)\n188 (136, 375)\n0.033*\n\n\nSucrose_Detected\n152\n40 (53%)\n39 (51%)\n0.741\n\n\nTaurine\n152\n8,683 (4,348, 15,166)\n8,361 (4,961, 18,043)\n0.575\n\n\nTaurine_Detected\n152\n69 (92%)\n74 (96%)\n0.324\n\n\nTheobromine\n152\n56,260 (31,562, 97,440)\n44,495 (27,195, 83,002)\n0.399\n\n\nThiamine\n152\n29,981 (17,516, 69,874)\n23,791 (15,054, 53,231)\n0.176\n\n\nThiamine_Detected\n152\n74 (99%)\n75 (97%)\n&gt;0.999\n\n\nThreonine\n152\n18,376 (12,710, 47,559)\n17,283 (12,037, 28,124)\n0.413\n\n\nThreonine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nTrimethylamine\n152\n6,796 (5,631, 13,068)\n7,063 (4,811, 10,299)\n0.295\n\n\nTrimethylamine_Detected\n152\n46 (61%)\n57 (74%)\n0.094\n\n\nTrimethylamine_N_Oxide\n152\n1,773,778 (1,192,615, 2,890,172)\n1,514,715 (1,090,219, 2,587,975)\n0.718\n\n\nTryptamine\n152\n39,928 (24,601, 61,038)\n38,902 (24,217, 62,809)\n0.611\n\n\nTryptamine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nTryptophan\n152\n18,310 (8,787, 32,368)\n16,906 (12,142, 30,463)\n0.930\n\n\nTyrosine\n152\n5,716 (3,099, 13,048)\n6,329 (4,596, 9,649)\n0.320\n\n\nTyrosine_Detected\n152\n70 (93%)\n73 (95%)\n0.744\n\n\nUracil\n152\n3,050 (2,121, 4,689)\n2,803 (2,082, 3,571)\n0.129\n\n\nUracil_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nUric_Acid\n152\n1,424 (548, 3,491)\n1,376 (968, 2,078)\n0.642\n\n\nUric_Acid_Detected\n152\n61 (81%)\n67 (87%)\n0.337\n\n\nValine\n152\n28,561 (18,677, 55,543)\n29,328 (20,031, 40,656)\n0.748\n\n\nValine_Detected\n152\n71 (95%)\n77 (100%)\n0.057\n\n\nXanthine\n152\n14,320 (10,020, 20,161)\n13,944 (9,222, 17,723)\n0.371\n\n\nXanthine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nA_Ketoglutaric_Acid\n152\n906 (639, 2,006)\n768 (507, 1,183)\n0.073\n\n\nA_Ketoglutaric_Acid_Detected\n152\n72 (96%)\n77 (100%)\n0.118\n\n\nG_Aminobutyric\n152\n430 (319, 793)\n394 (312, 613)\n0.336\n\n\nG_Aminobutyric_Detected\n152\n38 (51%)\n34 (44%)\n0.422\n\n\nLeucine_Isoleucine_Ratio\n152\n34,037 (22,022, 63,119)\n33,026 (24,933, 48,315)\n0.721\n\n\nLeucine_Isoleucine_Ratio_Detected\n152\n73 (97%)\n75 (97%)\n&gt;0.999\n\n\n\nUnits are in peak area. P-values are unadjusted.\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\nTyrosine–Tryptophan Pathway\n\n\n\n\n\n\nTryptophan Urine Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nTryptophan Urine Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~60)\n\np-value2,3\n\n\nNO\nN = 741\nYES\nN = 761\n\n\n\n\nHippuric_Acid\n150\n499 (260, 886)\n400 (223, 666)\n0.017*\n\n\nP_Cresol_Sulfate\n150\n93 (43, 142)\n88 (47, 145)\n0.990\n\n\n5HIAA_Sulfate\n150\n0.08 (0.05, 0.12)\n0.07 (0.04, 0.12)\n0.179\n\n\n5HIAA\n150\n1.24 (0.98, 1.82)\n1.19 (0.93, 1.50)\n0.169\n\n\nDopamine\n150\n0.07 (0.05, 0.09)\n0.06 (0.04, 0.08)\n0.166\n\n\nHomovanilic_Acid\n150\n1.23 (0.92, 1.89)\n1.25 (0.88, 1.63)\n0.714\n\n\nIndole\n150\n0.94 (0.67, 1.34)\n0.77 (0.60, 1.24)\n0.249\n\n\nIndoxyl_Sulfate\n150\n42 (23, 56)\n35 (21, 55)\n0.397\n\n\nIndole3Acetic_Acid\n150\n0.74 (0.38, 1.95)\n0.84 (0.44, 1.48)\n0.708\n\n\nP_Coumaric_Acid_Sulfate\n150\n0.06 (0.02, 0.11)\n0.03 (0.02, 0.05)\n0.003**\n\n\nP_Coumaric_Acid\n150\n0.06 (0.03, 0.12)\n0.05 (0.03, 0.08)\n0.090\n\n\nP_Ethylphenol_Sulfate\n150\n34 (20, 78)\n21 (12, 41)\n0.001**\n\n\nP_HBA\n150\n327 (215, 449)\n317 (199, 459)\n0.829\n\n\nP_HBA_Sulfate\n150\n3,030 (1,586, 5,277)\n2,785 (1,269, 6,187)\n0.912\n\n\nPhenylalanine\n150\n3.73 (2.75, 5.88)\n4.17 (2.85, 6.23)\n0.386\n\n\nP_Hydroxyphenyl_Acetic_Acid_Sulfate\n150\n0.42 (0.25, 0.66)\n0.43 (0.23, 0.71)\n0.954\n\n\nP_Hydroxyphenylpropionic_Acid_Sulfate\n150\n0.006 (0.003, 0.009)\n0.004 (0.002, 0.008)\n0.374\n\n\nP_Hydroxyphenyllactic_Acid_Sulfate\n150\n1.70 (1.30, 2.15)\n1.47 (1.15, 1.82)\n0.030*\n\n\nTryptophan\n150\n3.03 (2.28, 4.34)\n3.50 (2.47, 4.94)\n0.293\n\n\nTyramine\n150\n0.28 (0.21, 0.37)\n0.30 (0.21, 0.35)\n0.838\n\n\nTyrosine\n150\n26 (18, 39)\n30 (22, 42)\n0.068\n\n\nKynurenine\n150\n0.24 (0.16, 0.37)\n0.27 (0.15, 0.52)\n0.352\n\n\nIndole3Lactic_Acid\n150\n0.23 (0.14, 0.38)\n0.15 (0.10, 0.23)\n0.001**\n\n\nKynurenic_Acid\n150\n1.42 (0.99, 2.00)\n1.15 (0.68, 2.01)\n0.195\n\n\nP_Hydroxyphenyllactic_Acid\n150\n0.05 (0.03, 0.07)\n0.03 (0.02, 0.05)\n&lt;0.001***\n\n\nP_Hydroxyphenyl_Acetic_Acid\n150\n10 (7, 15)\n8 (6, 13)\n0.098\n\n\nPhenol_Sulfate\n150\n8 (4, 13)\n4 (3, 9)\n0.011*\n\n\n\nUnits are in μg/mmol of creatinine. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "modeling2.html",
    "href": "modeling2.html",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Prioritizing heterogeneous data sources (demographics, clinical, omics, digital health) in building a predictive/association model for metabolic syndrome (MetS). The aim is to balance (i) clinical interpretability, (ii) cost/feasibility, and (iii) explanatory power.\n\n\n\nThe goal is to build models that progress from broad, upstream, easily interpretable determinants of MetS to fine-grained, mechanistic, or exploratory markers.\nSo the ordering reflects a conceptual causal and interpretability hierarchy, not statistical performance:\n\nFrom distal → proximal → mechanistic → exploratory\n\nThis mirrors how we reason biologically and clinically:\n\nWho is at risk? (demographics, behavior)\nWhat modifiable exposures or interventions exist? (diet, medication)\nWhat physiological manifestations are measurable in routine care? (clinical biochemistry)\nWhat molecular signatures explain underlying pathways? (targeted metabolites → untargeted omics)\n\n\n\n\n\nExamples: age, sex, ethnicity, socioeconomic status, education, family history\n\n\n\nThese are fundamental, non-modifiable determinants that shape all downstream biology and behaviors.\nThey act as baseline confounders or stratifiers for almost every other dataset (e.g., age and sex affect biochemistry, metabolomics, and disease risk).\nCollected reliably, at low cost, and are always available.\nThey provide context for interpreting later findings (e.g., age-related differences in metabolites).\n\n\n\n\n\nAlways start here to define baseline risk and to adjust all subsequent models.\n\n\n\n\n\n\nExamples: Healthy Eating Index, Mediterranean Diet Score, physical activity questionnaires, smoking, alcohol, sleep questionnaires\n\n\n\nRepresent modifiable exposures that directly influence metabolic health.\nThey often precede disease onset and affect biomarkers downstream (lipids, glucose, metabolites).\nThey connect public-health interventions to molecular outcomes.\nEven if self-reported, they capture long-term habits not seen in blood/metabolite snapshots.\n\n\n\n\n\nKey upstream, modifiable factors that influence nearly every physiological pathway related to MetS.\n\n\n\n\n\n\nExamples: antihypertensives, statins, metformin, GLP-1 agonists, etc.\n\n\n\nStrongly influence downstream biochemical and metabolomic readouts.\nRepresent clinical interventions that modify the phenotype of interest.\nMust be accounted for to distinguish disease biology from drug effects.\nOften act as confounders or effect modifiers in biomarker analyses.\n\n\n\n\n\nCritical to adjust for before interpreting any biological signal — they change metabolic readouts directly.\n\n\n\n\n\n\nExamples: objectively measured activity, step count, energy expenditure, sleep metrics, heart rate variability\n\n\n\nProvide objective, continuous measures of lifestyle and physiology, complementing self-reported behaviors.\nReflect real-time metabolic demand and stress, bridging behavior and physiology.\nMore proximal than lifestyle but still modifiable and behavioral in nature.\nIncreasingly reliable with modern wearables, but still variable across devices and populations.\n\n\n\n\n\nObjective bridge between behavior and physiology; still upstream of biochemical consequences.\n\n\n\n\n\n\nExamples: glucose, insulin, HbA1c, triglycerides, HDL, LDL, CRP, liver enzymes\n\n\n\nReflect established diagnostic and mechanistic markers of metabolic syndrome components (dyslipidemia, insulin resistance, inflammation).\nRoutinely measured, standardized, and directly interpretable.\nRepresent proximal physiological consequences of earlier exposures.\nProvide the foundation for defining MetS itself (waist circumference, TG, HDL, glucose, blood pressure).\n\n\n\n\n\nDirectly linked to the clinical phenotype; serve as both outcomes and mediators of upstream factors.\n\n\n\n\n\n\nExamples: amino acids, sugars, acylcarnitines, bile acids, short-chain fatty acids\n\n\n\nCapture specific biochemical pathways involved in energy metabolism, insulin signaling, fatty acid oxidation.\nProvide mechanistic insight beyond routine biochemistry.\nOften measurable with targeted LC-MS/MS → quantitative, interpretable, reproducible.\nReflect early molecular perturbations before clinical changes become apparent.\nRequire domain expertise for interpretation; not as standardized across labs as clinical chemistry.\n\n\n\n\n\nMechanistic layer connecting clinical phenotypes to molecular dysregulation; interpretable but downstream of physiology.\n\n\n\n\n\n\nExamples: creatinine, albumin, electrolytes, urinary metabolites\n\n\n\nReflects systemic metabolic waste and renal function — downstream consequence of blood biochemistry.\nUseful for normalization (e.g., creatinine) or secondary pathways (oxidative stress, kidney involvement).\nMore variable due to hydration, timing, diet; less directly interpretable mechanistically than plasma markers.\n\n\n\n\n\nSecondary biofluid — complementary but less directly connected to primary metabolic processes measured in blood.\n\n\n\n\n\n\nExamples: untargeted LC-MS, NMR, transcriptomics, proteomics, microbiome, methylomics\n\n\n\nHigh-dimensional, exploratory, and hypothesis-generating.\nContain potentially novel biomarkers, but also high noise and platform bias.\nHarder to interpret mechanistically without context from previous levels.\nUseful after upstream and targeted layers are understood or adjusted for.\nOften correlate with clinical and targeted data, so entering them last avoids overshadowing interpretable effects.\n\n\n\n\n\nDeep, hypothesis-generating molecular layer — biologically valuable but least interpretable and most context-dependent.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nLevel\nBlock\nRole in the MetS pathway\nTypical use in modeling\n\n\n\n\n1\nDemographics\nBaseline determinants, confounders\nAlways adjust first\n\n\n2\nDiet/lifestyle\nModifiable exposures\nCausal/behavioral drivers\n\n\n3\nMedications\nClinical interventions\nConfounders/effect modifiers\n\n\n4\nDevice data\nObjective behavior, physiology\nBridge between behavior & biology\n\n\n5\nClinical labs\nPhysiological biomarkers\nCore diagnostic information\n\n\n6\nTargeted metabolites\nMechanistic biomarkers\nLink pathways to phenotype\n\n\n7\nUrine\nSecondary metabolic output\nComplementary / kidney status\n\n\n8\nUntargeted omics\nExploratory molecular layer\nDiscover novel mechanisms\n\n\n\n\n\n\n\n\nWe start with who the person is (demographics), then what they do (diet & lifestyle), what’s done to them (medications), what their body does in real life (device data), how their physiology currently looks (clinical biochemistry), what’s happening mechanistically (targeted metabolites), what’s being excreted (urine), and finally what’s observable at the most granular molecular level (untargeted omics).\n\n\n\n\n\nThis order emphasizes parsimony and interpretability first, then mechanistic depth.\nStatistically, the analysis can be implemented as hierarchical modeling or block-wise regression (adding predictors in blocks and testing incremental R², likelihood ratio tests, or predictive accuracy).\nIf the aim is prediction only (not interpretation), sometimes statistical learning SL algorithms can integrate all blocks simultaneously i.e. partial least squares and variants, least absolute shrinkage and selection operator (lasso) — at the expense of losing the interpretative clarity of the priority approach. However, even if prediction is the sole goal, the question is how much more the predictive performance is improved by including all available data into a model.\nMost SL algorithms that can be applied to small size data or high-dimensional data do not account for potential non-linear associations with a response variable, as well as not accounting for interactions among predictor variables. The priority approach here can handle those issues but in a less automatic manner.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#overall-logic-behind-the-priority-order",
    "href": "modeling2.html#overall-logic-behind-the-priority-order",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "The goal is to build models that progress from broad, upstream, easily interpretable determinants of MetS to fine-grained, mechanistic, or exploratory markers.\nSo the ordering reflects a conceptual causal and interpretability hierarchy, not statistical performance:\n\nFrom distal → proximal → mechanistic → exploratory\n\nThis mirrors how we reason biologically and clinically:\n\nWho is at risk? (demographics, behavior)\nWhat modifiable exposures or interventions exist? (diet, medication)\nWhat physiological manifestations are measurable in routine care? (clinical biochemistry)\nWhat molecular signatures explain underlying pathways? (targeted metabolites → untargeted omics)",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#demographics",
    "href": "modeling2.html#demographics",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Examples: age, sex, ethnicity, socioeconomic status, education, family history\n\n\n\nThese are fundamental, non-modifiable determinants that shape all downstream biology and behaviors.\nThey act as baseline confounders or stratifiers for almost every other dataset (e.g., age and sex affect biochemistry, metabolomics, and disease risk).\nCollected reliably, at low cost, and are always available.\nThey provide context for interpreting later findings (e.g., age-related differences in metabolites).\n\n\n\n\n\nAlways start here to define baseline risk and to adjust all subsequent models.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#dietary-indices-lifestyle-factors",
    "href": "modeling2.html#dietary-indices-lifestyle-factors",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Examples: Healthy Eating Index, Mediterranean Diet Score, physical activity questionnaires, smoking, alcohol, sleep questionnaires\n\n\n\nRepresent modifiable exposures that directly influence metabolic health.\nThey often precede disease onset and affect biomarkers downstream (lipids, glucose, metabolites).\nThey connect public-health interventions to molecular outcomes.\nEven if self-reported, they capture long-term habits not seen in blood/metabolite snapshots.\n\n\n\n\n\nKey upstream, modifiable factors that influence nearly every physiological pathway related to MetS.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#medications",
    "href": "modeling2.html#medications",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Examples: antihypertensives, statins, metformin, GLP-1 agonists, etc.\n\n\n\nStrongly influence downstream biochemical and metabolomic readouts.\nRepresent clinical interventions that modify the phenotype of interest.\nMust be accounted for to distinguish disease biology from drug effects.\nOften act as confounders or effect modifiers in biomarker analyses.\n\n\n\n\n\nCritical to adjust for before interpreting any biological signal — they change metabolic readouts directly.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#device-data",
    "href": "modeling2.html#device-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Examples: objectively measured activity, step count, energy expenditure, sleep metrics, heart rate variability\n\n\n\nProvide objective, continuous measures of lifestyle and physiology, complementing self-reported behaviors.\nReflect real-time metabolic demand and stress, bridging behavior and physiology.\nMore proximal than lifestyle but still modifiable and behavioral in nature.\nIncreasingly reliable with modern wearables, but still variable across devices and populations.\n\n\n\n\n\nObjective bridge between behavior and physiology; still upstream of biochemical consequences.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#clinical-blood-biochemistry",
    "href": "modeling2.html#clinical-blood-biochemistry",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Examples: glucose, insulin, HbA1c, triglycerides, HDL, LDL, CRP, liver enzymes\n\n\n\nReflect established diagnostic and mechanistic markers of metabolic syndrome components (dyslipidemia, insulin resistance, inflammation).\nRoutinely measured, standardized, and directly interpretable.\nRepresent proximal physiological consequences of earlier exposures.\nProvide the foundation for defining MetS itself (waist circumference, TG, HDL, glucose, blood pressure).\n\n\n\n\n\nDirectly linked to the clinical phenotype; serve as both outcomes and mediators of upstream factors.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#targeted-metabolites",
    "href": "modeling2.html#targeted-metabolites",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Examples: amino acids, sugars, acylcarnitines, bile acids, short-chain fatty acids\n\n\n\nCapture specific biochemical pathways involved in energy metabolism, insulin signaling, fatty acid oxidation.\nProvide mechanistic insight beyond routine biochemistry.\nOften measurable with targeted LC-MS/MS → quantitative, interpretable, reproducible.\nReflect early molecular perturbations before clinical changes become apparent.\nRequire domain expertise for interpretation; not as standardized across labs as clinical chemistry.\n\n\n\n\n\nMechanistic layer connecting clinical phenotypes to molecular dysregulation; interpretable but downstream of physiology.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#urine-data",
    "href": "modeling2.html#urine-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Examples: creatinine, albumin, electrolytes, urinary metabolites\n\n\n\nReflects systemic metabolic waste and renal function — downstream consequence of blood biochemistry.\nUseful for normalization (e.g., creatinine) or secondary pathways (oxidative stress, kidney involvement).\nMore variable due to hydration, timing, diet; less directly interpretable mechanistically than plasma markers.\n\n\n\n\n\nSecondary biofluid — complementary but less directly connected to primary metabolic processes measured in blood.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#untargeted-metabolomics-other-omics",
    "href": "modeling2.html#untargeted-metabolomics-other-omics",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Examples: untargeted LC-MS, NMR, transcriptomics, proteomics, microbiome, methylomics\n\n\n\nHigh-dimensional, exploratory, and hypothesis-generating.\nContain potentially novel biomarkers, but also high noise and platform bias.\nHarder to interpret mechanistically without context from previous levels.\nUseful after upstream and targeted layers are understood or adjusted for.\nOften correlate with clinical and targeted data, so entering them last avoids overshadowing interpretable effects.\n\n\n\n\n\nDeep, hypothesis-generating molecular layer — biologically valuable but least interpretable and most context-dependent.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#conceptual-summary-causal-and-interpretive-hierarchy",
    "href": "modeling2.html#conceptual-summary-causal-and-interpretive-hierarchy",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "Level\nBlock\nRole in the MetS pathway\nTypical use in modeling\n\n\n\n\n1\nDemographics\nBaseline determinants, confounders\nAlways adjust first\n\n\n2\nDiet/lifestyle\nModifiable exposures\nCausal/behavioral drivers\n\n\n3\nMedications\nClinical interventions\nConfounders/effect modifiers\n\n\n4\nDevice data\nObjective behavior, physiology\nBridge between behavior & biology\n\n\n5\nClinical labs\nPhysiological biomarkers\nCore diagnostic information\n\n\n6\nTargeted metabolites\nMechanistic biomarkers\nLink pathways to phenotype\n\n\n7\nUrine\nSecondary metabolic output\nComplementary / kidney status\n\n\n8\nUntargeted omics\nExploratory molecular layer\nDiscover novel mechanisms",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#summary-rationale",
    "href": "modeling2.html#summary-rationale",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "We start with who the person is (demographics), then what they do (diet & lifestyle), what’s done to them (medications), what their body does in real life (device data), how their physiology currently looks (clinical biochemistry), what’s happening mechanistically (targeted metabolites), what’s being excreted (urine), and finally what’s observable at the most granular molecular level (untargeted omics).\n\n\n\n\n\nThis order emphasizes parsimony and interpretability first, then mechanistic depth.\nStatistically, the analysis can be implemented as hierarchical modeling or block-wise regression (adding predictors in blocks and testing incremental R², likelihood ratio tests, or predictive accuracy).\nIf the aim is prediction only (not interpretation), sometimes statistical learning SL algorithms can integrate all blocks simultaneously i.e. partial least squares and variants, least absolute shrinkage and selection operator (lasso) — at the expense of losing the interpretative clarity of the priority approach. However, even if prediction is the sole goal, the question is how much more the predictive performance is improved by including all available data into a model.\nMost SL algorithms that can be applied to small size data or high-dimensional data do not account for potential non-linear associations with a response variable, as well as not accounting for interactions among predictor variables. The priority approach here can handle those issues but in a less automatic manner.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#device-data-1",
    "href": "modeling2.html#device-data-1",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Device Data",
    "text": "Device Data\nBy device data we mean the human body measurements as seen in the Data Processing & EDA page. Also a shorter list of those measurements was finally selected for potential inclusion into the model (the list was based on better measurement interpretation reasons).\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nSite_Collection\n\n\n2\nae\n\n\n3\npe\n\n\n4\nans_balance\n\n\n5\nstress_index\n\n\n6\nfatigue_index\n\n\n7\ngender\n\n\n8\nrisk_group_cardiovascular\n\n\n9\nage\n\n\n10\nbfm\n\n\n11\nwhr\n\n\n12\ntbw_ffm_ratio\n\n\n13\nbcm_t_score\n\n\n14\nkhz_whole_body_phase_angle_z_score\n\n\n\n\n\n\n\nLRT\nModel: MetS ~ Gender + rcs(xDevice) where xDevice is a predictor from the above list and rcs means that potential non-linear associations are taken into account.\nResults:\n\n\n\n\n\nrow\nvarName\nchisq\ndf\nanova_pval\nFDR_pval\n\n\n\n\n1\nbfm\n51.2432\n3\n0.0000\n0.0000\n\n\n2\nwhr\n31.0848\n3\n0.0004\n0.0022\n\n\n3\nbcm_t_score\n30.5236\n3\n0.0005\n0.0022\n\n\n4\nstress_index\n24.4287\n3\n0.0109\n0.0354",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#biochemical-data",
    "href": "modeling2.html#biochemical-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Biochemical Data",
    "text": "Biochemical Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nCHOL\n\n\n2\nLDL\n\n\n3\nHbA1c_Perc\n\n\n4\nUREA\n\n\n5\nCREA\n\n\n6\nOH_Vit_D3\n\n\n7\nALB\n\n\n8\nTBIL\n\n\n9\nNa\n\n\n10\nK\n\n\n11\nCRP\n\n\n12\nRBC\n\n\n13\nBASO_Perc\n\n\n14\nMVC\n\n\n15\nMCHC\n\n\n16\nRDW_CV_Perc\n\n\n17\nMONO\n\n\n18\nEOS\n\n\n19\nPLT\n\n\n20\nSGOT\n\n\n21\nSGPT\n\n\n22\nALP\n\n\n23\nAISI\n\n\n24\nPLR\n\n\n\n\n\n\n\nLRT\nThe following predictors are not considered as they use measurements that define the MetS: TRIG, HDL, GLU, TG_HDL_C_Index, CHOL_HDL_Ratio, TyG_Index and Atherogenic_Index.\nAlso a more liberal value for the FDR_pval threshold is used here: 10%\nModel: MetS ~ Gender + rcs(bfm,3) + rcs(whr,3) + rcs(bcm_t_score,3) + rcs(stress_index,3) + rcs(xBiochem,3) where xBiochem is a predictor from the above list and rcs means that potential non-linear associations are taken into account.\nResults:\n\n\n\n\n\nrow\nvarName\nchisq\ndf\nanova_pval\nFDR_pval\n\n\n\n\n1\nHbA1c_Perc\n75.4276\n11\n0.0007\n0.0168\n\n\n2\nALP\n71.0320\n11\n0.0066\n0.0792\n\n\n3\nTBIL\n70.0593\n11\n0.0107\n0.0856",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#amino-acids-sugars-data",
    "href": "modeling2.html#amino-acids-sugars-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Amino Acids & Sugars Data",
    "text": "Amino Acids & Sugars Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nAnhydroglucitol\n\n\n2\nGlucose\n\n\n3\nMannose\n\n\n4\nFructose\n\n\n5\nValine\n\n\n6\nIsoleucine\n\n\n7\nGlutamine\n\n\n8\nPhenylalanine\n\n\n9\nTyrosine\n\n\n10\nTryptophan\n\n\n11\nGlutamine_To_Glutamic_Acid_Ratio\n\n\n\n\n\n\n\nLRT\nModel: MetS ~ Gender + rcs(bfm,3) + rcs(whr,3) + rcs(bcm_t_score,3) + rcs(stress_index,3) + rcs(HbA1c_Perc,3) + rcs(ALP,3) + rcs(TBIL,3) + rcs(xAAS,3) where xAAS is a predictor from the above list and rcs means that potential non-linear associations are taken into account.\nResults:\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\nchisq\ndf\nanova_pval\nFDR_pval\n\n\n\n\n1\nGlutamine_To_Glutamic_Acid_Ratio\n93.668\n17\n0.003\n0.033",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#acylcarnitines-data",
    "href": "modeling2.html#acylcarnitines-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "AcylCarnitines Data",
    "text": "AcylCarnitines Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nAcetylcarnitine\n\n\n2\nPropionylcarnitine\n\n\n3\nButyrylcarnitine\n\n\n4\nValerylcarnitine\n\n\n5\nLauroylcarnitine\n\n\n6\nStearoylcarnitine\n\n\n7\nLinoleoylcarnitine\n\n\n8\nOleoylcarnitine\n\n\n\n\n\n\n\nLRT\nModel: MetS ~ Gender + rcs(bfm,3) + rcs(whr,3) + rcs(bcm_t_score,3) + rcs(stress_index,3) + rcs(HbA1c_Perc,3) + rcs(ALP,3) + rcs(TBIL,3) + rcs(Glutamine_To_Glutamic_Acid_Ratio,3) + rcs(xAcylCar,3) where xAcylCar is a predictor from the above list and rcs means that potential non-linear associations are taken into account.\nResults: No significant cases",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#urine-hydrophilic-interaction-liquid-chromatography-hilic-data",
    "href": "modeling2.html#urine-hydrophilic-interaction-liquid-chromatography-hilic-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Urine Hydrophilic Interaction Liquid Chromatography (HILIC) Data",
    "text": "Urine Hydrophilic Interaction Liquid Chromatography (HILIC) Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nHydroxyisovalericacid\n\n\n2\nMethylhistidine\n\n\n3\nAcetylcarnitine\n\n\n4\nAllantoin\n\n\n5\nAscorbic_Acid\n\n\n6\nBetaine\n\n\n7\nCaffeine\n\n\n8\nCotinine\n\n\n9\nCreatine\n\n\n10\nCytosine\n\n\n11\nGuanine\n\n\n12\nHippuric_Acid\n\n\n13\nHistamine\n\n\n14\nHypoxanthine\n\n\n15\nInosine\n\n\n16\nKynurenate\n\n\n17\nLactose\n\n\n18\nLysine\n\n\n19\nMethylamine\n\n\n20\nNicotinamide\n\n\n21\nPantothenate\n\n\n22\nRivoflavine\n\n\n23\nSorbitol\n\n\n24\nTaurine\n\n\n25\nTheobromine\n\n\n26\nThiamine\n\n\n27\nTrimethylamine\n\n\n28\nTrimethylamine_N_Oxide\n\n\n29\nTryptamine\n\n\n30\nUracil\n\n\n31\nXanthine\n\n\n32\nA_Ketoglutaric_Acid\n\n\n\n\n\n\n\nLRT\nModel: MetS ~ Gender + rcs(bfm,3) + rcs(whr,3) + rcs(bcm_t_score,3) + rcs(stress_index,3) + rcs(HbA1c_Perc,3) + rcs(ALP,3) + rcs(TBIL,3) + rcs(Glutamine_To_Glutamic_Acid_Ratio,3) + rcs(log(xHILIC),3) where xHILIC is a predictor from the above list and rcs means that potential non-linear associations are taken into account.\nResults:\n\n\n\n\n\nrow\nvarName\nchisq\ndf\nanova_pval\nFDR_pval\n\n\n\n\n1\nInosine\n106.281\n19\n7e-04\n0.0224",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#urine-tyrosinetryptophan-pathway-data",
    "href": "modeling2.html#urine-tyrosinetryptophan-pathway-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Urine Tyrosine–Tryptophan Pathway Data",
    "text": "Urine Tyrosine–Tryptophan Pathway Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nHippuric_Acid\n\n\n2\nP_Cresol_Sulfate\n\n\n3\nHIAA_Sulfate\n\n\n4\nHIAA\n\n\n5\nDopamine\n\n\n6\nHomovanilic_Acid\n\n\n7\nIndole\n\n\n8\nIndoxyl_Sulfate\n\n\n9\nIndole3Acetic_Acid\n\n\n10\nP_Coumaric_Acid_Sulfate\n\n\n11\nP_Coumaric_Acid\n\n\n12\nP_Ethylphenol_Sulfate\n\n\n13\nP_HBA\n\n\n14\nP_HBA_Sulfate\n\n\n15\nPhenylalanine\n\n\n16\nP_Hydroxyphenyl_Acetic_Acid_Sulfate\n\n\n17\nP_Hydroxyphenylpropionic_Acid_Sulfate\n\n\n18\nP_Hydroxyphenyllactic_Acid_Sulfate\n\n\n19\nTyramine\n\n\n20\nKynurenine\n\n\n21\nIndole3Lactic_Acid\n\n\n22\nKynurenic_Acid\n\n\n23\nP_Hydroxyphenyllactic_Acid\n\n\n24\nP_Hydroxyphenyl_Acetic_Acid\n\n\n25\nPhenol_Sulfate\n\n\n\n\n\n\n\nLRT\nA more liberal value for the FDR_pval threshold is used here: 15%\nModel: MetS ~ Gender + rcs(bfm,3) + rcs(whr,3) + rcs(bcm_t_score,3) + rcs(stress_index,3) + rcs(HbA1c_Perc,3) + rcs(ALP,3) + rcs(TBIL,3) + rcs(Glutamine_To_Glutamic_Acid_Ratio,3) + rcs(log(Inosine),3) + rcs(xTyroTrypto,3) where xTyroTrypto is a predictor from the above list and rcs means that potential non-linear associations are taken into account.\nResults:\n\n\n\n\n\nrow\nvarName\nchisq\ndf\nanova_pval\nFDR_pval\n\n\n\n\n1\nIndole3Lactic_Acid\n116.5835\n21\n0.0051\n0.1275",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#untargeted-metabolomics",
    "href": "modeling2.html#untargeted-metabolomics",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Untargeted metabolomics",
    "text": "Untargeted metabolomics\nAwaiting data provision.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#selected-predictors",
    "href": "modeling2.html#selected-predictors",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Selected Predictors",
    "text": "Selected Predictors\nThe final model formula is as follows:\nMetS ~ Gender + rcs(bfm,3) + rcs(whr,3) + rcs(bcm_t_score,3) + rcs(stress_index,3) + rcs(HbA1c_Perc,3) + rcs(ALP,3) + rcs(TBIL,3) + rcs(Glutamine_To_Glutamic_Acid_Ratio,3) + rcs(log(Inosine),3) + rcs(Indole3Lactic_Acid,3) where rcs means that potential non-linear associations are taken into account.\nThe predictors selected also show univariate differentiation ability of the MetS score as seen in the page. The only exception is the predictor bcm_t_score which in isolation does not show differentiation whereas when included in the model is does. This seems to occur due to a suppresion effect of the Gender predictor, which effectively increases the predictive validity of bcm_t_score by improving its relationship with the outcome.\nbcm_t_score and the related predictor bcm are associated with Gender as witnessed in the redundancy analysis of the device data. For instance the cumulative R-squared values when modeling Gender using these two related predictors is seen below in parentheses:\ngender ~ bcm (0.573) + bcm_t_score (0.931)\n\n\n\n\n\n\n\n\nFigure 2: Gender differentiation of the bcm at first data collection time.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 3: bcm_t_score differentiation of the MetS index at first data collection time. With a flat regression line the association is weak.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Female\n\n\n\n\n\n\n\n\n\n\n\n(b) Male\n\n\n\n\n\n\n\nFigure 4: bcm_t_score differentiation of the MetS index when grouped by Gender and at first data collection time. Conditional on Gender the association of bcm_t_score with the MetS index becomes stronger as seen by the upward trending regression lines.\n\n\n\n \nPredictors from device data in relation with BMI which is used to define the response MetS\n\n\n\n\n\n\n\n\n\n\n\n(a) bfm\n\n\n\n\n\n\n\n\n\n\n\n(b) whr\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) bcm_t_score\n\n\n\n\n\n\n\n\n\n\n\n(d) stress_index\n\n\n\n\n\n\n\nFigure 5: Device predictors in relation to BMI. With exception of the stress_index, the other predictors seem to be associated with BMI. The outlier value corresponds to a BMI = 68.4 value.\n\n\n\nOutlier based on large BMI value",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "eda2.html",
    "href": "eda2.html",
    "title": "Data Processing & EDA",
    "section": "",
    "text": "Compared to version 1 in this version missing values from the biochemical data have been filled either by correction or missing value imputation. As a result the number of observations has increased from ~123 in version 1 to ~153 in this version i.e. a ~25% increase. The ~ approximation here is to denote the fact that depending on the type of analysis and the data sets involved, the number of observations could change a bit to 120 instead of 123 in version 1, and to 150 in this version.\nClick here for the codiet project’s site.",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  }
]